Upregulation of Renin Angiotensin Aldosterone System (RAAS) by Methylglyoxal: Role in Hypertension

A Thesis

Submitted to the College of Graduate Studies and Research

In Partial Fulfillment of the Requirements For the Degree of Doctor of Philosophy

In the Department of Pharmacology

University of Saskatchewan

Canada

By

INDU DHAR

© Copyright Indu Dhar, December 2013. All rights reserved.
PERMISSION TO USE

In presenting this thesis in partial fulfillment of the requirements for a Postgraduate degree from the University of Saskatchewan, I agree that the Libraries of this University may make it freely available for inspection. I further agree that permission for copying of this thesis in any manner, in whole or in part, for scholarly purposes may be granted by the professor or professors who supervised my thesis work or, in their absence, by the Head of the Department or the Dean of the College in which my thesis work was done. It is understood that any copying or publication or use of this thesis or parts thereof for financial gain shall not be allowed without my written permission. It is also understood that due recognition shall be given to me and to the University of Saskatchewan in any scholarly use which may be made of any material in my thesis.

Requests for permission to copy or to make other use of material in this thesis in whole or part should be addressed to:

Head of the Department of Pharmacology
University of Saskatchewan
Saskatoon, Saskatchewan S7N 5E5
Canada

Or

Dean, College of Medicine
University of Saskatchewan
Saskatoon, Saskatchewan S7N 5E5
Canada
ABSTRACT

In 2008 the global prevalence of hypertension [high blood pressure (BP), systolic ≥140 mmHg and/or diastolic ≥90 mmHg] was around 40% in adults > 25 yrs of age, according to the 2013 WHO statistics. Hypertension is a major risk factor for myocardial infarction, heart failure and stroke. Currently, around 20% of the Canadian population is affected by hypertension. Hypertension is more closely associated with diabetes. More than two thirds of people with diabetes have hypertension, along with increased activity of the renin angiotensin aldosterone (RAAS) system. The RAAS plays a major role in maintaining fluid balance, vascular tone and BP. The components of the RAAS include the hormone renin, which cleaves angiotensinogen, a circulating inactive peptide into angiotensin I. Angiotensin converting enzyme (ACE) converts angiotensin I into the active peptide angiotensin II (Ang II). Ang II causes vasoconstriction, sodium reabsorption from the kidney tubules and also release of the hormone, aldosterone, from the adrenal cortex. The epidemic of hypertension, diabetes and obesity is widely attributed to a high carbohydrate diet, containing mainly high fructose corn syrup and sucrose. However, the underlying molecular mechanisms are far from clear. A high fructose diet increases BP in Sprague-Dawley (SD) rats; along with elevated plasma and aortic levels of methylglyoxal (MG). MG is a reactive dicarbonyl compound mainly formed as an intermediate during glycolysis. Small amounts of MG are also formed during amino acid (threonine) and fatty acid metabolism. MG reacts with certain proteins to form irreversible advanced glycation end products (AGEs). MG has high affinity for arginine, lysine and cysteine. Plasma MG levels are increased in hypertensive rats and diabetic patients. However, it is not yet clear whether MG is the cause or effect of hypertension. Moreover, safe and specific MG scavengers are not available.

The aim of the project was to determine the effect of MG and a high fructose diet on the
RAAS and the BP in male SD rats. The hypothesis that L-arginine, and its inactive isomer D-arginine, can efficiently scavenge MG in vitro, was also tested.

Male SD rats were treated with a continuous infusion of MG with a subcutaneous minipump for 4 weeks, or with a high fructose diet (60% of total calories) for 16 weeks. We also used isolated aortic rings from 12 week old normal male SD rats to study endothelial function. Organs / tissues, cultured human umbilical vein endothelial cells (HUVECs) and vascular smooth muscle cells (VSMCs) were used for molecular studies. HPLC, Western blotting and Q-PCR were used to measure MG, reduced glutathione (GSH), proteins and mRNA, respectively. siRNA for angiotensinogen and the receptor for advanced glycation endproducts (RAGE) were used to study mechanisms.

MG treated rats developed a significant increase in BP and plasma levels of aldosterone, renin, angiotensin and catecholamines. MG level, and protein and mRNA for angiotensin, AT\textsubscript{1} receptor, adrenergic $\alpha_{1D}$ receptor and renin were significantly increased in the aorta and/or kidney of MG treated rats, a novel finding. Alagebrium, a MG scavenger and AGEs breaker, attenuated the above effects of MG. Treatment of cultured VSMCs with MG or high glucose (25mM) significantly increased cellular MG, and protein and mRNA for nuclear factor kappa B (NF-κB), angiotensin, AT\textsubscript{1} and $\alpha_{1D}$ receptors, which were prevented by inhibition of NF-κB, and by alagebrium. Silencing of mRNA for RAGE prevented the increase in NF-κB induced by MG. Silencing of mRNA for angiotensinogen prevented the increase in NF-κB, angiotensin, AT\textsubscript{1} and $\alpha_{1D}$ receptors’ protein. Fructose treated rats developed a significant increase in BP. MG level and protein and mRNA for angiotensin II, AT\textsubscript{1} receptor, adrenergic $\alpha_{1D}$ receptor and renin were significantly increased, whereas GSH levels were decreased, in the aorta and/or kidney of fructose fed rats. The protein expression of the receptor for AGEs (RAGE) and NF-κB were also
significantly increased in the aorta of fructose fed rats. MG treated VSMCs showed increased protein for angiotensin II, AT₁ receptor, and α₁D receptor. The effects of fructose and MG were attenuated by metformin, a MG scavenger and AGEs inhibitor. In experiments to test the MG scavenging action of arginine, both D-arginine and L-arginine prevented the attenuation of acetylcholine-induced endothelium-dependent vasorelaxation by MG and high glucose. However, the inhibitory effect of the NOS inhibitor, Νω-nitro-L-arginine methyl ester, on vasorelaxation was prevented only by L-arginine, but not by D-arginine. MG and high glucose increased protein expression of arginase, a novel finding, and also of NADPH oxidase 4 and NF-κB, and production of reactive oxygen species in HUVECs and VSMCs, which were attenuated by D- and L-arginine. However, D- and L-arginine did not attenuate MG and high glucose-induced increased arginase activity in VSMCs and the aorta. D- and L-arginine also attenuated the increased formation of the MG-specific AGE, Nε-carboxyethyl lysine, caused by MG and high glucose in VSMCs.

In conclusion, MG activates NF-κB through RAGE and thereby increases renin angiotensin levels, a novel finding, and a probable mechanism of increase in BP. There is a strong association between elevated levels of MG, RAGE, NF-κB, mediators of the RAAS and BP in high fructose diet fed rats. Arginine attenuates the increased arginase expression, oxidative stress, endothelial dysfunction and AGEs formation induced by MG and high glucose, by an endothelial NOS independent mechanism.
DEDICATIONS

to

Dr. Arti Dhar

who groomed me and made me who I am today and is

my real life mentor, the biggest role model and a true blessing from God

&

to the Almighty who made it all possible
ACKNOWLEDGEMENTS

Foremost, I would like to thank my supervisor, Dr. Kaushik Desai for giving me an opportunity to work with him as a Master’s and later as a PhD student and all the support, guidance and encouragement. I am very grateful to him for valuable ideas, training and financial support which was instrumental in creating this thesis. I appreciate him for being a friend, and supportive mentor. I want to thank him for providing me intellectual space and challenging me which made me a confident and an independent researcher. He is an excellent researcher, wonderful human being, and a best guide for me.

I would also like to express my deepest appreciation to my co-supervisor Dr Lingyun Wu for her scientific knowledge, comments, and funding during my PhD work.

I would also like to express my express gratitude to my advisory committee: Drs. Steven Richardson, Kailash Prasad, Tom Wilson, and Lynn Weber for their guidance, valuable insights, and constructive criticism whenever necessary. A special thanks to Dr. Kailash Prasad for his great help in giving comprehensive advice on my work, and being very helpful in personal life as well.

Working on the thesis was a challenging and interesting venture and I was blessed to have insightful and patient colleagues: Dr Arti Dhar, Dr Jianghai Liu, Yang Su, Dr Tuanjie Chang, Arlene Drimmie, Qian Huang, and Ashley Untereiner. It would be unfair if I miss out to give special credit to Dr. Arti Dhar in particular for teaching me all the tedious techniques at the beginning of my course and providing assistance all the time. It was a pleasure working with you.
and I am sure lessons taught by you will be the supporting pillar to my future professional as well as personal endeavours.

I also appreciate people in our department: Cindy Wruck, Donna Dodge, Bob Wilcox, and Corinne Howells for their assistance, friendship and care during all these years.

I would like to thank my father Sh. Moti Lal Dhar for his undying love, support and encouragement to always keep my head high no matter what the situation demands. I would also like to thank my mother Usha Dhar, sister Goldy Bhat, brother Rahul, and niece Savee for their continuous support and love. I would also like to express my deepest gratitude to my close comrade Sunney Fotedar for his understanding, encouragement and energetic discussions during these years which made me a strong individual.

My thesis couldn’t have been possible without the support from The Department of Pharmacology, College of Medicine, Heart and Stroke Foundation of Saskatchewan, Saskatchewan Health Research Foundation and Canadian Institutes of Health Research. I hope they will continue the good work and recognize good research areas.

Finally, I want to thank God for his love, faith, mercy and blessing us with little Aariv.
TABLE OF CONTENTS

ABSTRACT ii
DEDICATION v
ACKNOWLEDGEMENTS vi
TABLE OF CONTENTS viii
LIST OF FIGURES xiii
LIST OF TABLES xvii
LIST OF ABBREVIATIONS xviii

CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 1

1.1 Hypertension 2
   1.1.a Definition 2
   1.1.b Prevalence 3
   1.1.c Classification 4
   1.1.d Regulation of BP 6
   1.1.e Pathogenesis 12
   1.1.f Hypertension in diabetes 14
   1.1.g Glucose and fructose induced hypertension 16
   1.1.h Treatment 17
1.2 Methylglyoxal (MG)

1.2.a Source & Chemistry

1.2.b Synthesis & degradation

1.2.c Plasma & tissue levels

1.2.d MG & AGEs

1.2.e MG & oxidative stress

1.2.f MG & endothelial dysfunction

1.2.g MG scavengers

CHAPTER 2: HYPOTHESIS AND OBJECTIVES

2.1 Rationale for hypothesis

2.2 Hypothesis

2.3 Objectives and experimental approach

2.3.a To investigate whether MG is a causative factor in the pathogenesis of hypertension and the underlying molecular mechanism

2.3.b To investigate the effects of a high fructose diet on components of the RAAS and the peripheral adrenergic system in Sprague-Dawley rats

2.3.c To investigate whether arginine can attenuate methylglyoxal- and high glucose-induced endothelial dysfunction
CHAPTER 3. GENERAL METHODOLOGY

3.1 Animals
3.2 Cell culture
3.3 MG assay
3.4 Western blotting
3.5 Real time PCR
3.6 Arginase activity assay
3.7 Measurement of reactive oxygen species
3.8 Immunocytochemistry
3.9 Isometric tension studies on aortic rings
3.10 Plasma assays
3.11 siRNA transfection
3.12 Measurement of reduced glutathione (GSH)

PUBLICATIONS AND THEIR RELATION TO THE THESIS

CHAPTER 4. METHYLGLYOXAL, A REACTIVE GLUCOSE METABOLITE, INCREASES RENIN ANGIOTENSIN ALDOSTERONE AND BLOOD PRESSURE IN SPRAGUE-DAWLEY RATS: ATTENUATION BY ALAGEBRIUM

4.1 Abstract
4.2 Introduction
CHAPTER 5. INCREASED METHYLGLYOXAL FORMATION
WITH UPREGULATION OF RENIN ANGIOTENSIN SYSTEM
IN FRUCTOSE FED SD RATS
5.1 Abstract
5.2 Introduction
5.3 Methods
5.4 Results
5.5 Discussion

CHAPTER 6. ARGinine ATTENUATES METHYLGLYOXAL
AND HIGH GLUCOSE-INDUCED ENDOTHELIAL DYSFUNCTION
BY AN ENOS-INDEPENDENT MECHANISM
6.1 Abstract
6.2 Introduction
6.3 Methods
6.4 Results
6.5 Discussion

CHAPTER 7. DISCUSSION AND CONCLUSION
7.1 General discussion 132

7.2 Conclusion 138

7.3 Limitations 139

7.4 Significance 142

REFERENCES 143
<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-1</td>
<td>Pathway of regulation of BP by renin angiotensin aldosterone system.</td>
<td>10</td>
</tr>
<tr>
<td>1-2</td>
<td>Pathogenesis of hypertension</td>
<td>13</td>
</tr>
<tr>
<td>1-3</td>
<td>Chemical structure of methylglyoxal</td>
<td>20</td>
</tr>
<tr>
<td>1-4</td>
<td>Metabolic pathways of MG formation and degradation</td>
<td>22</td>
</tr>
<tr>
<td>1-5</td>
<td>Pathway of AGEs formation by MG</td>
<td>25</td>
</tr>
<tr>
<td>1-6</td>
<td>Mechanisms of MG induced oxidative stress</td>
<td>28</td>
</tr>
<tr>
<td>1-7</td>
<td>Mechanism of Nitric oxide mediated endothelium-dependent relaxation and endothelial dysfunction</td>
<td>31</td>
</tr>
<tr>
<td>1-8</td>
<td>Chemical structure of alagebrium</td>
<td>35</td>
</tr>
<tr>
<td>1-9</td>
<td>Chemical structure of L-arginine</td>
<td>37</td>
</tr>
<tr>
<td>4-1</td>
<td>Methylglyoxal levels in cultured vascular smooth muscle cells and in the aorta and kidney of chronic methylglyoxal treated Sprague-Dawley rats.</td>
<td>72</td>
</tr>
<tr>
<td>4-2</td>
<td>Mean arterial blood pressure, plasma catecholamines, angiotensin renin, and aldosterone levels in chronic methylglyoxal treated Sprague-Dawley rats.</td>
<td>73</td>
</tr>
<tr>
<td>4-3</td>
<td>$\alpha_{1D}$ receptor, AT$_1$ receptor and angiotensin protein expression in cultured vascular smooth muscle cells and in the aorta amd mRNA in VSMCs and aorta of chronic methylglyoxal treated Sprague-Dawley rats.</td>
<td>74</td>
</tr>
</tbody>
</table>
Figure 4-4  AT₁ receptor, renin and angiotensin protein expression and mRNA in the kidney of chronic methylglyoxal treated Sprague-Dawley rats.

Figure 4-5  Phosphorylated extracellular signal-related kinases 1/2 (p-Erk 1/2), Erk 1/2 and NFATc expression in cultured vascular smooth muscle cells and in the aorta and kidney (C) of chronic methylglyoxal treated Sprague-Dawley rats.

Figure 4-6  Nuclear factor κB (NF-κB), angiotensin, AT₁ receptor, α₁D receptor and receptor for advanced glycation endproducts (RAGE) expression in cultured vascular smooth muscle cells treated with a NF-κB inhibitor or or after RAGE siRNA or angiotensinogen siRNA treatment.

Figure 4-S1  α₁D receptor, AT₁ receptor and angiotensin expression in cultured vascular smooth muscle cells treated with methylglyoxal or high glucose after RAGE siRNA or angiotensinogen siRNA treatment.

Figure 5-1  Mean arterial blood pressure and methylglyoxal (MG) levels in the aorta and kidney of high fructose diet treated Sprague-Dawley rats.

Figure 5-2  Adrenergic α₁D receptor (α₁DR), AT₁ angiotensin receptor (AT₁R) and angiotensin II (Ang II) expression and mRNA in the aorta of high fructose diet treated Sprague-Dawley rats.

Figure 5-3  AT₁ angiotensin receptor (AT₁R), renin and angiotensin II (Ang II) expression and mRNA in the kidney of high fructose diet treated Sprague-Dawley rats.

Figure 5-4  Phosphorylated extracellular signal-related kinases 1/2 (p-Erk 1/2), Erk 1/2 and NFATc expression in the aorta and kidney of high fructose
diet treated Sprague-Dawley rats.

**Figure 5-5** Receptor for advanced glycation endproducts (RAGE) and nuclear factor κB (NF-κB) expression in the aorta and kidney of high fructose diet treated Sprague-Dawley rats.

**Figure 5-6** Reduced glutathione (GSH) levels in the aorta and kidney of high fructose diet treated Sprague-Dawley rats.

**Figure 5-7** α1D receptor (α1D R), AT1 receptor (AT1 R) and Angiotensin II (Ang II) expression in cultured vascular smooth muscle cells (VSMCs) treated with methylglyoxal.

**Figure 6-1** L-arginine and D-arginine attenuate MG and high glucose, but not inhibition of eNOS-induced, reduced endothelium-dependent relaxation in isolated aortic rings from Sprague–Dawley rats.

**Figure 6-2** Exogenous methylglyoxal (MG) and high glucose and increase cellular MG levels in cultured vascular smooth muscle cells: attenuation by L-arginine (L-Arg) and D-arginine (D-Arg).

**Figure 6-3** Attenuation by L-arginine and D-arginine of methylglyoxal (MG) and high glucose-induced increased protein expression, but not activity of arginase (Agn) I and II in cultured human umbilical vein endothelial cells (HUVECs) and vascular smooth muscle cells (VSMCs).

**Figure 6-4** Attenuation by L-arginine and D-arginine of methylglyoxal (MG) and high glucose-induced increased protein expression of nuclear factor kappa B (NF-κB) and NADPH oxidase 4 (NOX-4) in cultured human umbilical vein endothelial cells (HUVECs) and vascular smooth...
muscle cells (VSMCs).

Figure 6-5  Attenuation by L-arginine and D-arginine of methylglyoxal (MG) and high glucose-induced increased reactive oxygen species production in cultured human umbilical vein endothelial cells (HUVECs).

Figure 6-6  Attenuation by L-arginine and D-arginine of methylglyoxal (MG) and high glucose-induced increased reactive oxygen species production in cultured rat aortic vascular smooth muscle cells (VSMCs).

Figure 6-7  Detection of methylglyoxal-induced advanced glycation endproduct $N^c$-carboxyethyl-lysine (CEL).
LIST OF TABLES

Table 1-1  Stages of hypertension based on change in systolic and diastolic blood pressure  3

Table 1-2  Lifestyle causes of increase in BP  4

Table 1-3  Classification of hypertension.  5

Table 5-1  In vitro assay to determine the methylglyoxal (MG) scavenging ability of metformin.  101

Table 6-1  MG incubation assay  130
LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-MQ</td>
<td>2-methyl quinoxaline</td>
</tr>
<tr>
<td>3-DG</td>
<td>3-Deoxyglucosone</td>
</tr>
<tr>
<td>5-MQ</td>
<td>5-methyl quinoxaline</td>
</tr>
<tr>
<td>AG</td>
<td>Aminoguanidine</td>
</tr>
<tr>
<td>AGEs</td>
<td>Advanced glycation end products</td>
</tr>
<tr>
<td>ALA</td>
<td>Alagebrium</td>
</tr>
<tr>
<td>ALD</td>
<td>Aldosterone</td>
</tr>
<tr>
<td>ANG</td>
<td>Angiotensin</td>
</tr>
<tr>
<td>ANG II</td>
<td>Angiotensin II</td>
</tr>
<tr>
<td>ANOVA</td>
<td>One way analysis of variance</td>
</tr>
<tr>
<td>AT1</td>
<td>Angiotensin receptor subtype 1</td>
</tr>
<tr>
<td>DHAP</td>
<td>Dihydroxyacetone phosphate</td>
</tr>
<tr>
<td>DM</td>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco’s modified eagle medium</td>
</tr>
<tr>
<td>EC</td>
<td>Endothelial cells</td>
</tr>
<tr>
<td>eNOS</td>
<td>Endothelial nitric oxide synthase</td>
</tr>
<tr>
<td>G-3-P</td>
<td>Glyceraldehyde-3-phosphate</td>
</tr>
<tr>
<td>GSH</td>
<td>Reduced glutathione</td>
</tr>
<tr>
<td>GSH-Red</td>
<td>Glutathione reductase</td>
</tr>
<tr>
<td>H$_2$O$_2$</td>
<td>Hydrogen peroxide</td>
</tr>
<tr>
<td>HPLC</td>
<td>High performance liquid chromatography</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>HUVECs</td>
<td>Human umbilical vein endothelial cells</td>
</tr>
<tr>
<td>MG</td>
<td>Methylglyoxal</td>
</tr>
<tr>
<td>NAC</td>
<td>N-acetyl L-cysteine</td>
</tr>
<tr>
<td>NO</td>
<td>Nitric oxide</td>
</tr>
<tr>
<td>O$_2$(^{-})</td>
<td>Superoxide</td>
</tr>
<tr>
<td>ONOO(^{-})</td>
<td>Peroxynitrite</td>
</tr>
<tr>
<td>(\alpha)-PD</td>
<td>Ortho phenylene diamine</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate buffered saline</td>
</tr>
<tr>
<td>PCA</td>
<td>Perchloric acid</td>
</tr>
<tr>
<td>PI3K</td>
<td>Phosphoinositide 3 kinsase</td>
</tr>
<tr>
<td>RAAS</td>
<td>Renin angiotensin aldosterone system</td>
</tr>
<tr>
<td>RAECs</td>
<td>Rat aortic endothelial cells</td>
</tr>
<tr>
<td>RAGEs</td>
<td>Receptor for advanced glycation end products</td>
</tr>
<tr>
<td>ROS</td>
<td>Reactive oxygen species</td>
</tr>
<tr>
<td>SD</td>
<td>Sprague-Dawley</td>
</tr>
<tr>
<td>SSAO</td>
<td>Semicarbazide-sensitive amine oxidase</td>
</tr>
<tr>
<td>VSMCs</td>
<td>Vascular smooth muscle cells</td>
</tr>
<tr>
<td>(\alpha)(_1)D</td>
<td>Alpha adrenergic receptor subtype D</td>
</tr>
</tbody>
</table>
CHAPTER 1

INTRODUCTION AND LITERATURE REVIEW
1.1 Hypertension

1.1.a Definition

Hypertension, also defined as high blood pressure, is a medical condition in which the blood pressure (BP) in the arteries stays persistently elevated. BP is the force of blood pushing up against the arterial vessel walls. The higher the pressure, the harder it requires the heart to pump the blood. BP is measured as systolic pressure i.e., peak pressure in the arteries, and diastolic pressure i.e., minimum pressure in the arteries. Normal BP is usually below 120/80 mmHg where 120 mmHg represents systolic and 80 mmHg represents diastolic pressure (Giles et al., 2009; Chobanian et al., 2003). A BP value between 120/80 mmHg and 139/89 mmHg is called prehypertension and BP above 140/90 mmHg is considered hypertension (Table 1-1). 90-95% cases of hypertension are characterized as primary (formerly also known as essential hypertension) with no apparent medical cause. 5-10% cases are secondary hypertension with a known cause such as kidney disease, tumors and heart disease (Carretero & Oparil, 2000). Although the exact cause/causes of hypertension is/are not known, there are several factors such as smoking, obesity, diabetes, lack of physical activity, high levels of salt intake, stress, aging, and tumors, which contribute to its development (Klaus et al., 2009; Elley et al., 2002) (Table 1-2). Hypertension is a major risk factor for stroke, ischemic heart disease, heart failure and chronic kidney disease (Coca et al., 2008; Hatmi et al., 2007).
Stages of Hypertension

<table>
<thead>
<tr>
<th>Category</th>
<th>SBP (mmHg)</th>
<th>DBP (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>&lt;120</td>
<td>&lt;80</td>
</tr>
<tr>
<td>Prehypertension</td>
<td>120-139</td>
<td>80-89</td>
</tr>
<tr>
<td>Hypertension, Stage 1</td>
<td>140-159</td>
<td>90-99</td>
</tr>
<tr>
<td>Hypertension, Stage 2</td>
<td>≥160</td>
<td>≥100</td>
</tr>
</tbody>
</table>


1.1.b Prevalence

In 2013, the World Health Organization chose hypertension as the theme for the World Health Day which was celebrated on April 7, 2013 ([Campbell et al., 2013](http://www.cdc.gov/features/worldhealthhypertension/)). The World Health Day highlights a topic that is a public health concern. The global prevalence of high BP in adults aged 25 years and above was around 40% (around 2.7 billion out of 6.7 billion people) in 2008. The number of people with uncontrolled hypertension was around 600 million in 1980 and rose to 1 billion by
the year 2008. High BP is estimated to cause 7.5 million deaths worldwide every year, which accounts for about 12.8% of the total number of deaths (http://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence_text/en/). Canada has the highest reported national rates of awareness, treatment, and control of high BP in the world. The prevalence of hypertension in Canada has remained fairly constant at around 20% of the 26 million people included in the retrospective study, for the past three decades (1985-2011) (Campbell et al., 2013).

<table>
<thead>
<tr>
<th>Lifestyle</th>
<th>Risk of hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td>High dietary sodium</td>
<td>32%</td>
</tr>
<tr>
<td>Obesity</td>
<td>32%</td>
</tr>
<tr>
<td>Low dietary potassium</td>
<td>17%</td>
</tr>
<tr>
<td>Less physical activity</td>
<td>17%</td>
</tr>
<tr>
<td>High alcohol intake</td>
<td>3%</td>
</tr>
</tbody>
</table>

Table 1-2: Lifestyle causes of increase in the BP. Adapted from *Can J Cardiol*. 2013; 29:415-417.

1.1.c Classification of Hypertension

Hypertension can also be classified (Table 1-3) based on cardiovascular risk factors, early disease markers and target organ disease as follows:
<table>
<thead>
<tr>
<th>Classification</th>
<th>Normal Hypertension</th>
<th>Stage I</th>
<th>Hypertension Stage 2</th>
<th>Hypertension Stage 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Description</strong></td>
<td>Normal BP &amp; no CVD</td>
<td>Intermittent or occasional BP elevation and early CVD</td>
<td>Sustained elevation of BP or progressive CVD</td>
<td>Marked elevation of BP or advanced CVD</td>
</tr>
<tr>
<td>Cardiovascular risk factors</td>
<td>-</td>
<td>Several risk factors present</td>
<td>Many risk factors</td>
<td>Many risk factors</td>
</tr>
<tr>
<td>Early disease markers</td>
<td>-</td>
<td>Present</td>
<td>Present</td>
<td>Present with progression</td>
</tr>
<tr>
<td>Target organ disease</td>
<td>-</td>
<td>-</td>
<td>Early signs</td>
<td>Present</td>
</tr>
</tbody>
</table>

**Table 1-3: Classification of hypertension. Adapted from J Clin Hypertens. 2009 Nov;11(11):611-4.**

Cardiovascular risk factors - Aging, obesity, dyslipidemia, insulin resistance, kidney disease etc.
Early disease markers - Loss of nocturnal BP dipping, left ventricular hypertrophy, artery stiffness, endothelial dysfunction, microalbuminuria, elevated serum creatinine.

Target organ disease - Left ventricular hypertrophy, peripheral arterial disease, stroke, heart failure and neuropathy

CVD – cardiovascular disease

1.1.d Regulation of BP

There are many factors which can influence BP like diet, exercise, disease condition and stress. One main physical factor involved in BP physiology is the volume of blood. When there is more blood present in the body, the rate of blood return to the heart is higher resulting in higher cardiac output (Freis, 1975). Another factor influencing BP is vascular resistance or better still, peripheral vascular resistance. Higher the resistance, higher will be the pressure upstream from the resistance to blood flow. Resistance is calculated by vessel radius, vessel length, and blood viscosity. Larger the vessel radius, lower the resistance, and longer the vessel, higher is the resistance. Smoothness of the vessel wall is affected by the buildup of fatty deposits on the arterial walls and thickness or viscosity of the fluid (Rosenson et al., 2004). If the blood gets thicker, this results in an increase in arterial pressure. Certain medical conditions like anemia (low red blood cell count) reduce viscosity of the blood.

The short term regulation of BP is controlled by the sympathetic nervous system (SNS) and the renin angiotensin aldosterone (RAAS) system while long term BP is controlled by the kidney.
Normal BP is usually below 120/80 mmHg. Parameters influencing systolic pressure include stroke volume, systolic rate and arterial compliance. An increase in stroke volume, systolic rate and a decrease in compliance cause an increase in systolic pressure. Factors influencing diastolic pressure include vascular resistance, heart rate and systolic pressure. Diastolic pressure is directly proportional to these factors (Prasad, 2009).

**Baroreceptor and chemoreceptor reflex**

Baroreceptors, located in the carotid sinus at the bifurcation of the common carotid artery and aortic arch, respond to acute elevations in BP by causing a reflex vagal bradycardia. Cardio pulmonary receptors, located in the pulmonary vessels and in the walls of the right atrium and the ventricles of the heart, likewise respond to increases in atrial filling by causing bradycardia through inhibition of cardiac SNS, increasing atrial natriuretic peptide (ANP) release and inhibition of vasopressin release (Prasad, 2009).

Chemoreceptors, located at the bifurcation of the carotid artery and aortic arch, respond to changes in blood pO₂, pCO₂ and pH. Chemoreceptors are stimulated when either pO₂, pH, or the blood flow in the arteries is very low, or when the pCO₂ is high. In response to these changes, the chemoreceptors send impulses to cause vasoconstriction and increase the vascular resistance, heart rate and stroke volume via increased sympathetic activity (Prasad, 2009).

**Sympathetic nervous system**

The sympathetic nervous system (SNS) through renal sympathetic nerves also plays an important role in BP regulation by stimulating renin release from the juxtaglomerular apparatus (Joyner et al., 2010). α₁-adrenergic receptors, one of the subtypes of adrenergic receptors, belong to the G protein-coupled receptor (GPCR) family and mediate responses to norepinephrine and
epinephrine. $\alpha_1$-adrenergic receptors are further subdivided into $\alpha_{1A}$, $\alpha_{1B}$ and $\alpha_{1D}$ using receptor binding and molecular cloning studies (Zhong & Minneman, 1999). All three $\alpha_1$-adrenergic receptor subtypes act via Gq/11 signaling pathway. Gq/11 signaling activation in turn leads to activation of phospholipase C, generation of inositol trisphosphate and diacylglycerol, and finally an increase in intracellular calcium levels (Piascik & Perez, 2001; Pupo & Minneman, 2001). Although all three $\alpha_1$ adrenergic receptor subtypes activate the same Gq/11 protein signaling pathway, due to their different tissue distributions, they play distinct functional roles. $\alpha_{1A}$ adrenergic receptor is highly expressed in the prostate and is the dominant receptor controlling benign prostatic hypertrophy, and is thus an important therapeutic target for the treatment of benign prostatic hyperplasia (Nagarathnam et al., 1998). $\alpha_{1D}$ is the major adrenergic receptor in the aorta and is responsible for the contraction of the aorta (Fan et al., 2009). WB 4101[13], (+)-niguldipine (Boer et al., 1989), and 5-methylurapidil (Gross et al., 1988) have been used as $\alpha_{1A}$ selective antagonists, and BMY7378 (Goetz et al., 1995) is used to characterize $\alpha_{1D}$ adrenergic receptors. However, little progress has been made to identify $\alpha_{1B}$ adrenergic receptor selective compounds. Three $\alpha_2$ receptor subtypes have been identified, $\alpha_{2A/D}$, $\alpha_{2B}$ and $\alpha_{2C}$. Most of the classical effects of $\alpha_2$ adrenergic stimulation are mediated by pre-synaptic $\alpha_{2A}$ receptors, which inhibit the release of norepinephrine, and cause a decrease in BP. $\alpha_{2B}$ adrenergic receptors are mostly found at postsynaptic sites where they produce vasoconstriction and thus have effects opposite to those of $\alpha_{2A}$ receptors. $\alpha_{2C}$ adrenergic receptors may mediate a hypothermic response and do not have cardiovascular effects (Joyner et al., 2010).
Renin angiotensin aldosterone system

The activity of the RAAS plays an important role in BP regulation. Renin is a 340 amino acid protein with a molecular weight of 37 kDa. As shown in (Fig 1-1), renin is secreted by the kidney from granular cells of the juxtaglomerular apparatus in response to a decrease in the BP, low salt levels in the nephron and an increase in the SNS activity. Renin breaks down angiotensinogen, produced by the liver, to an inactive decapeptide, angiotensin I. Angiotensin I is further converted into the active octapeptide angiotensin II (Ang II) by the angiotensin converting enzyme (ACE) within the capillaries (Atlas, 2007).

The amount of renin in the plasma acts as a limiting factor for Ang II production. Apart from Ang II generated in the circulation, blood vessels capture circulating renin and angiotensinogen and produce Ang II at the surface of their wall. Many tissues like blood vessels, heart, kidney, and brain possess all components of the renin angiotensin system and generate Ang II inside their cells. Ang II is involved in electrolyte balance, blood volume and pressure homeostasis. The most important action of Ang II is vasoconstriction produced directly as well as by increasing epinephrine/norepinephrine release and increasing central sympathetic outflow. Vasoconstriction involves arterioles and venules and occurs in all vascular beds. Ang II induced vasoconstriction promotes movement of fluid from the vascular to the extravascular compartment. Ang II increases the force of myocardial contraction by increasing Ca^{2+} influx.

Aldosterone is a steroid hormone belonging to the mineralocorticoid family. It is produced by the zona glomerulosa of the adrenal cortex in the adrenal gland. Aldosterone plays a central role in BP regulation by acting on the distal tubules and collecting ducts of the nephron,
increasing reabsorption of sodium ions and water in the kidney, to cause the conservation of sodium, secretion of potassium and increased water retention (Booth et al., 2002).

ADH, also known as antidiuretic hormone, is synthesized in the hypothalamus and stored in the posterior pituitary. ADH release is increased by Ang II. ADH plays a role in water reabsorption in the renal tubules, which in turn causes increased fluid volume, cardiac output and later on increased vascular resistance and then finally increased arterial pressure (Prasad, 2009).

Although the pharmacological inhibition of the RAAS using ACE inhibitors and AT\textsubscript{1} receptor blockers can be beneficial in certain conditions including hypertension, a growing body of evidence suggests that blocking the RAAS at its initial step, \textit{i.e.}, renin inhibition may provide an effective RAAS suppression. Aliskiren is an orally active direct renin inhibitor and was approved by the U.S. Food and Drug Administration in 2007 for the treatment of primary hypertension. Aliskiren, by inhibiting renin, prevents angiotensin I generation from angiotensinogen, and thus subsequently prevents the activation of the rest of the RAAS (Wood \textit{et al.}, 2003).

Angiotensin I can also be converted to angiotensin (1-9) by angiotensin converting enzyme 2 (ACE2) and angiotensin (1-9) can be converted to angiotensin (1-7) by ACE. Angiotensin (1-7) is an active member of the RAAS system and has functions opposite to those of Ang II. Angiotensin (1-7) acts via a G protein-coupled receptor called Mas (Santos \textit{et al.}, 2003; Santos \textit{et al.}, 2005). AVE0991 is a non-peptide angiotensin (1–7) receptor Mas agonist, and its administration in coronary artery ligated rats attenuated post-ischemic heart failure induced by myocardial infarction (Ferreira \textit{et al.}, 2007a). AVE0991 also prevented isoproterenol-induced impairment in heart function/remodeling in the rat (Ferreira \textit{et al.}, 2007b). It has been reported recently that angiotensin (1-9) antagonizes pro-hypertrophic signaling in cardiomyocytes \textit{via} angiotensin type 2 (AT\textsubscript{2}) receptors (Flores-Muñoz \textit{et al.}, 2011). Renin, ACE2, angiotensin (1-7) and angiotensin (1-9) are potential therapeutic targets and need further investigation for the prevention and treatment of cardiovascular disorders (Balakumar \textit{et al.}, 2011).
1.1.e Pathogenesis of Hypertension

In general, hypertension is caused by both genetic and environmental factors (Oparil et al., 2003). The hereditability of blood pressure in humans has been estimated at 30-50% (Ehret & Caulfield., 2013).

Although several factors contribute to the pathogenesis of hypertension, renal mechanisms play a fundamental role. Mean arterial pressure is the product of cardiac output and systemic vascular resistance and patients with hypertension may either have an increase in cardiac output, an increase in systemic vascular resistance, or both. Regulation of normal BP is dependent on the balance between cardiac output and peripheral vascular resistance and most patients with primary hypertension have a normal cardiac output but raised peripheral resistance (Beevers et al., 2001). In young patients the cardiac output is often elevated, while in older patients increased systemic vascular resistance and increased vascular stiffness are the contributing factors. The tone of the vessel may be elevated due to increased release of peptides (angiotensin, endothelin) or increased alpha receptor stimulation. The final outcome is an increase in cytosolic calcium in vascular smooth muscle cells (VSMCs) causing vasoconstriction (Foex & Sears, 2004). Hypertension (Fig 1-2) is usually a result of complex interaction of genetic, environmental and demographic factors. Hypertension also causes vascular and cardiac remodeling and hypertrophy which in turn leads to a change in the structure and function of the heart and vessel wall (Mayet & Hughes, 2003). Enhanced peripheral sensitivity to norepinephrine and decreased sensitivity to baroreceptor reflexes has also been observed in hypertensive patients (Foex & Sears, 2004). Increased activity of the RAAS has also been
suggested as one of the contributing factors in the pathogenesis of hypertension (Oparil et al., 2003).

Figure 1-2. Pathogenesis of hypertension. Adapted from Ann Intern Med. 2003;139:761-776.

Abbreviations: Ald - aldosterone; Ang - angiotensinogen; CO – cardiac output; GIT – gastrointestinal tract; Ins - insulin; SA – sympathetic activation.

SNS over activity increases BP via stimulation of the heart, peripheral vasculature, and kidney thus causing increased cardiac output, increased vascular resistance, and fluid retention.
Chronic stimulation of the SNS induces vascular remodeling and left ventricular hypertrophy, by direct action of norepinephrine on its own receptors and indirectly via release of various trophic factors such as transforming growth factor, insulin-like growth factor 1, and fibroblast growth factors (Brook & Julius, 2000). Sympathetic stimulation is also increased in the kidney in hypertensive patients compared with normotensive control patients. Psychological stress is also one of the contributing factors to increases in BP. It has been reported that exposure to stress increases sympathetic outflow, and constant stress induces vasoconstriction which in turn may lead to vascular hypertrophy, increases in peripheral resistance and BP (Light, 2000).

Hyperuricemia, characterized by abnormally high uric acid levels in the blood, is also associated with hypertension in humans, but whether it is an independent risk factor or only a marker for associated CVD risk factors is not clear (Rich, 2000; Culleton et al., 1999). In human patients hyperuricemia is associated with renal vasoconstriction (Messerli et al., 1980) and is positively correlated with plasma renin activity in hypertensive patients (Saito et al., 1978), thus indicating that uric acid could have adverse effects that are mediated by an activated RAAS system.

1.1.f Hypertension in Diabetes

Approximately 70% of patients with diabetes have hypertension and it is twice more common in patients with diabetes than without it (Arya, 2003). Hypertension in diabetic patients causes a significant risk of other complications like retinopathy, neuropathy, nephropathy and ischemic vascular disease (Arya, 2003). Diabetes mellitus is also an independent risk factor for coronary artery disease and the risk is significantly higher when hypertension is present. In patients with type 1 diabetes, diabetic nephropathy is the commonest cause of hypertension in
patients. In patients with type 2 diabetes hypertension commonly occurs without abnormal renal function and is often associated with obesity. Diabetes and insulin resistance can aggravate hypertension by stimulating the renin angiotensin system, the SNS and sodium retention (Lago et al., 2007; Campbell et al., 2011). Increased VSMC proliferation has also been observed under diabetic conditions. High BP and elevated blood glucose levels can impair vascular endothelial cell function which in turn leads to increased oxidative stress (Kolluru et al., 2012; Giacco & Brownlee, 2010). Patients with diabetes also have increased vascular reactivity (Chittari et al., 2011).

The pathogenesis of hypertension in diabetes is multifactorial and complex. Interactions between genetic, environmental and biological factors such as sedentary behavior, unhealthy diet, sodium retention, obesity, autonomic derangements, arterial stiffening, and endothelial dysfunction seem to play an important role (Campbell, 2011). Insulin resistance plays a pivotal role in the pathogenesis of hypertension. In many randomized controlled trials patients with diabetes have benefited from a more aggressive treatment of hypertension. Insulin resistance plays a role in the development of hypertension via defects in the insulin signaling pathway and associated cardiovascular and metabolic disorders. Insulin resistance and its accompanying hyperglycemia can lead to increased sympathetic activity, increased RAAS activity, suppressed atrial natriuretic peptide activity, and increased sodium retention with volume expansion, cardiac hyperactivity, and dyslipidemia. Chronic hyperglycemia causes increased oxidative stress (Sampanis & Zamboulis, 2008). Pregnant women with hypertension and diabetes are at increased risk of developing pre-ecclampsia (Allison et al., 2013), and children with diabetes and hypertension are vulnerable to end organ disease (Lago et al., 2007).
1.1.g Glucose and Fructose Induced Hypertension

The intake of refined sugar in the diet increased dramatically in the latter part of the twentieth century after it was widely manufactured from sugar cane (Yudkin, 1967). In the 1970s the introduction of high-fructose corn syrup, a mixture of glucose and fructose in varying proportions, further increased the carbohydrate load in the diet because high fructose corn syrup is widely used in soft drinks, fruit punches, bread, and processed foods (Yudkin, 1967). In 1960s Yudkin proposed that the sugar in the diet, and not fat, is the primary cause of increased incidence of diabetes and various cardiovascular diseases (Yudkin, 1964). Epidemiologic studies show an association of soft drink consumption with obesity, hypertension, and diabetes (Schulze et al., 2004; Bray et al., 2004).

Two thirds of the patients with primary hypertension have an abnormal blood glucose metabolism (Garcia-Puig et al., 2006). Several studies have shown that administration of a high carbohydrate diet significantly increases BP in animals and humans. In a clinical study, the administration of sucrose significantly increased body weight, serum triacylglycerols, and systolic BP (Raben et al., 2002). Similarly, healthy adults fed a diet of 33% sucrose for 6 weeks showed an increase in BP (Israel et al., 1983). Oral administration of 10% D-glucose to normal rats for 3 weeks induced hypertension (Tom et al., 2011). Male Sprague-Dawley (SD) rats fed a glucose-rich diet developed a 7% increase in BP compared to rats fed a normal diet. Higher norepinephrine excretion in glucose fed rats suggests that increased SNS activity might participate in the glucose-induced rise in BP (Kaufman et al., 1991). Fructose-fed SD rats have been widely used as a model of insulin resistance (Hwang et al., 1987; Jia & Wu, 2007) and these rats also develop hypertension. For example, SD rats fed with a diet containing 66%
fructose as a percentage of total calories for approximately 2 weeks developed a significant increase in systolic blood pressure from 124 $\pm$ 2 to 145 $\pm$ 2 (SEM) mmHg, whereas no change occurred in the control group. In addition, hyperinsulinemia and hypertriglyceridemia were associated with hypertension in fructose-fed rats (Hwang et al., 1987). In other studies male SD rats fed a 60% fructose diet for 8-11 weeks developed a significant increase in systolic BP, other features of the metabolic syndrome (Nakagawa et al., 2006) and pathologic changes in the kidney (Sanchez-Lozada et al., 2007; Gersch et al., 2007). We have shown that fructose-fed SD rats have elevated levels of MG (Wang et al., 2008), a product of fructose metabolism. Even lower doses of fructose (10% in drinking water) given to SD rats for 8 weeks induced a significant increase in systolic BP and microvascular changes in the kidney (Sanchez-Lozada et al., 2007). High dietary carbohydrate-induced hypertension is associated with an increase in uric acid concentrations (Sanchez-Lozada et al., 2007; Gersch et al., 2007) with a consequent increase in oxidative stress (Sautin et al., 2007) and inhibition of NO production (Khosla et al., 2005). One study has reported that fructose-induced hypertension is mediated by an increase in salt re-absorption by the intestine and kidneys, and these effects are mediated by transporters Slc26a6 and Slc2a5 (Singh et al., 2008).

1.1.h Treatment of Hypertension

Treatment for hypertension can be achieved with lifestyle changes along with medications. There are different classes of drugs available for the prevention and management of hypertension.
ACE inhibitors are often the first choice drugs in all grades of primary hypertension as well as renovascular hypertension. They include captopril, enalapril, lisinopril etc. (Ajayi et al., 1985). ACE inhibitors increase plasma kinin levels such as bradykinin and potentiate the hypotensive action of bradykinin. ACE inhibitors induce hypotension by decreasing total peripheral resistance. The arterioles dilate and compliance of large arteries is increased. Both systolic and diastolic BP fall without change in cardiac output. They are the most appropriate drugs for diabetic nephropathy, left ventricular hypertrophy, congestive heart failure and angina pectoris (Brown & Vaughan, 1998).

Over the years several nonpeptide orally active AT$_1$ receptor antagonists have been developed. Losartan, candesartan and telmisartan are included in this class. AT$_1$ receptor antagonists are now first line antihypertensive drugs alternative to ACE inhibitors in efficacy, with the advantage of not inducing cough, and with a low incidence of angioedema. AT$_1$ receptor antagonists cause competitive antagonism of Ang II and are 10,000 times more selective for AT$_1$ than AT$_2$ receptors. They block all the actions of Ang II including vasoconstriction, central and peripheral sympathetic stimulation, release of aldosterone and vasopressin release (Fabia et al., 2007; Unger, 2001).

A large number of chemically diverse calcium channel blockers (CCBs) with different pharmacological profiles have been produced. Three important classes are: verapamil - a phenylalkylamine hydrophilic papaverine congener, nifedipine - a dihydropyridine (lipophilic), diltiazem - a hydrophilic benzothiazepine. The dihydropyridines are the most potent CCBs. CCBs cause smooth muscle (vascular) relaxation by decreasing intracellular availability of Ca$^{2+}$
Diuretics have been the standard antihypertensive drugs over the last 4 decades. These include thiazide diuretics like chlorthalidone, which act by decreasing extracellular fluid volume and ultimately leading to a decrease in total peripheral resistance and fall in BP. Another class of drugs in this category is the high ceiling diuretics like furosemide which act by decreasing plasma volume and cardiac output (Ernst & Moser, 2009; Musini et al., 2009).

Beta adrenergic receptor blockers are mild antihypertensives and do not lower the BP in normotensives. Alpha adrenergic receptor blockers or antagonists like prazosin dilate both resistance and capacitance vessels, with the former effect predominating. They cause a reduction in total peripheral resistance and mean BP with a slight decrease in venous return and cardiac output (Cruickshank, 2010; Stokes & Marwood, 1985).

Another group of antihypertensive drugs is central sympatholytics like clonidine, which is a partial agonist and has a high affinity for α2A receptors in the brainstem. The major effect of α2A receptor stimulation is a decrease in the sympathetic outflow resulting in a fall in BP and bradycardia, which is also due to enhanced vagal tone (Vongpatanasin et al., 2011).

1.2 Methylglyoxal

1.2.a Source and Chemistry of Methylglyoxal

Methylglyoxal (MG) (Fig 1-3), also called 2-oxopropanal or pyruvaldehyde, is an aldehyde with two carbonyl groups, and hence is also called a dicarbonyl compound. It is a yellow liquid with a pungent odour and has a molecular weight of 72.06. MG is both an aldehyde
and a ketone. Since MG has two $\alpha,\beta$ carbonyl groups, this makes it a highly reactive compound, reacting with exposed arginine, lysine and cysteine residues of proteins, and with other macromolecules such as DNA, in the body.

![Chemical structure of methylglyoxal](image)

**Figure 1-3. Chemical structure of methylglyoxal**

### 1.2.b Synthesis and Degradation of MG

MG was first synthesized from iso-nitrosoacetone in the presence of dilute sulfuric acid along with the formation of glycol, formaldehyde and formate by Von Penchmann (Von Penchmann, 1887), who first developed the method for the synthesis of MG. MG can also be formed from acid hydrolysis of methylglyoxal dimethylacetal and from the oxidation of acetone with selenium dioxide followed by distillation under nitrogen atmosphere (Kalapos, 1999).

In living organisms (Fig 1-4), MG is an endogenous metabolite and has been proposed to be primarily formed during glycolysis from the triose phosphate intermediates. Other important precursors of MG, believed to produce lower amounts of MG, include aminoacetone, produced from amino acids L-threonine and glycine during protein catabolism, and ketone bodies such as acetone from fatty acid oxidation. MG formation from these sources involves various enzymatic
and nonenzymatic reactions, but the main enzymes which catalyze MG formation from these precursors include: MG synthase, semicarbazide-sensitive amine oxidase (SSAO) and mono-oxygenase (MO). MG synthase catalyzes the conversion of triose phosphate intermediate, dihydroxyacetone phosphate (DHAP), into MG, under inadequate availability of inorganic phosphate. SSAO catalyzes the deamination of aminoactone to produce aldehyde, ammonia and hydrogen peroxide. Two enzymes, i.e. acetone and acetol mono-oxygenase (AMO), catalyze the conversion of acetone to acetol and acetol to MG, respectively, during fatty acid oxidation. SSAO is primarily found in the cytoplasm of adipose tissue, VSMCs, plasma and endothelial cells (Thornalley, 1996; Desai & Wu, 2007).

MG formed is rapidly detoxified to D-lactic acid by the glyoxalase system, which consists of 2 enzymes, glyoxalase I and II, and uses reduced glutathione (GSH) as a cofactor. GSH binds to MG and presents it to glyoxalase I, which first converts MG irreversibly to (S)-D-lactoylglutathione and then by glyoxalase II to D-lactate. Hence, adequate availability of cellular GSH is crucial for normal catabolism of MG in the body. Also, GSH-related enzymes, including glutathione peroxidase and glutathione reductase are equally important as they are involved in the synthesis and recycling of GSH (Thornalley, 1990).
Figure 1-4. Metabolic pathways of MG formation and degradation. Adapted from Metabolism. 2008; 57(9):1211-20.

Schematic showing pathways, substrates and enzymes involved in the formation of MG in the body.

Abbreviations: AMO – acetol/acetone monooxygenase; DHAP – dihydroacetone phosphate; F-1,6-di-P – fructose-1,6-diphosphate; G-3-P – glyceraldehyde-3-phosphate; GSH – reduced glutathione; SSAO – semicarbazide-sensitive amine oxidase; ROS – reactive oxygen species.
1.2.c Plasma and Tissue Levels of MG

Under normal conditions, the plasma levels of MG are between 0.5 and 1.5 µM (Jia & Wu, 2007; Wang et al., 2007) and the levels increase as much as 2 to 4 fold under hypertensive and diabetic conditions (Wang et al., 2007; Beisswenger et al., 1999). An increased body of evidence suggests that there is a link between increased MG formation and hypertension but the exact mechanism is far from clear. Previous studies have reported higher MG levels in the plasma of spontaneously hypertensive rats (SHR) of 13.8 µM at 8 weeks of age and 33 µM at 20 weeks as compared to Wistar Kyoto (WKY) rats at the same age (9.1 and 14.2 µM). In the aorta and kidney of SHR, the MG levels were 2.5 nmol/mg protein and 0.3 nmol/mg protein, respectively, as compared to the WKY rats (1.5 nmol/mg protein and 0.2 nmol/mg protein, respectively) at the same age (Wang et al., 2004; Wang et al., 2005). In Sprague-Dawley rats fed with a high fructose diet for 9 weeks, there was a significant increase in serum MG levels to 3.2 µM compared to 1.8 µM in the control rats and the effect was attenuated by the MG scavenger N-acetyl cysteine (NAC) (Jia and Wu, 2007). Rat VSMCs incubated with a high concentration of glucose or fructose lead to increased MG formation along with an increase in oxidative stress (Dhar et al., 2008). High MG levels are related to diabetic microvascular complications including retinopathy, nephropathy and neuropathy, and diabetic macrovascular complications such as atherosclerosis.

1.2.d MG and Advanced Glycation Endproducts

Advanced glycation endproducts (AGEs) are harmful chemical entities and are complex, heterogeneous compounds produced from chemical modification of physiologic molecules of the
body during metabolic processes and have been implicated in diabetes related complications (Desai & Wu, 2007).

AGEs as shown in (Fig 1-5) are formed when reducing sugars such as glucose, react non-enzymatically with the amino group of proteins at their N terminal, and with lipids and nucleic acids. The non-enzymatic reaction is known as glycation and is an outcome of excess glucose in the body. It starts with the carbonyl group of sugar reacting with the protein to form a Schiff base, an unstable intermediate (Oya et al., 1999; Desai & Wu, 2007). The Schiff base later undergoes an arrangement to form a stable Amadori product and this stable Amadori product can undergo oxidation, degradation or rearrangement to form AGEs. This process is also known as the Maillard reaction or “browning reaction”, when amino acids form a brown coloured product while heated in the presence of reducing sugars (Maillard, 1916).

If Amadori products undergo oxidation then the end products formed are known as glycoxidation products such as AGEs like pentosidine and carboxymethyl-lysine (CML) (Ahmed et al., 1986; Sell & Monnier, 1989). Amadori rearrangement and sugar molecule fragmentation leads to the formation of reactive intermediate products known as $\alpha$-dicarbonyls or oxoaldehydes and include 3-deoxyglucose (3-DG), MG and glyoxal. The accumulation of the dicarbonyls leads to carbonyl stress causing damage and oxidative stress in the body (Chellan & Nagaraj, 1999).

These AGEs affect the normal function of various proteins and enzymes by forming covalent cross-links between proteins (Reddy et al., 1995) and thus lead to severe damage including diabetic retinopathy, nephropathy and aging.
MG can also lead to AGEs formation. MG and two other oxoaldehydes (3-DG and glyoxal) are considered to be the major source of intracellular AGEs formation. The non-enzymatic reaction of MG, not degraded by the glyoxalase system, with arginine or lysine residues of proteins forms irreversible AGEs, leading to cross linking and denaturation of proteins. The irreversible reaction of MG with arginine forms the AGEs, hydroimidazolone, Nε-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine and argpyrimidine, whereas the reaction between MG and lysine forms the AGEs Nε-carboxyethyllysine (CEL) and Nε-carboxymethyllysine (CML). Carbonyl precursors (MG, 3-DG and glyoxal) also form non-oxidative AGEs, which are non-fluorescent, such as methylglyoxal-lysine dimer (MOLD),
glyoxal-lysine dimer (GOLD) and deoxyglucosone-lysine dimer (DOLD). These AGEs can be detected by HPLC, ELISA and immunohistochemistry (Desai & Wu, 2007).

1.2.e MG and Oxidative Stress

Oxidative stress is the imbalance between reactive oxygen species (ROS) production and antioxidant defense mechanisms in the body, caused by either excess free radical or ROS generation or impaired anti-oxidant enzymes. Free radicals are atoms or molecules with an unpaired electron in the outer orbit. Oxygen derived free radicals such as superoxide anion, hydroxyl radical, and non-radicals such as hydrogen peroxide that do not have an unpaired orbiting electron, are known as reactive oxygen species (ROS) (Desai & Wu, 2008). ROS are chemically highly reactive.

The role of MG (Fig 1-6) in inducing oxidative stress in various cell types is well known. MG activates several pathways to increase oxidative stress. MG, both directly and via AGEs formation, increases the activity of p38 MAPK and expression of JNK. The increased activity of these enzymes increases the proinflammatory cytokines, such as interleukin-1β, interleukin 6, interleukin 8 and tumor necrosis factor (Kikuchi et al., 1999). MG has also been shown to increase the superoxide anion, hydrogen peroxide and peroxynitrite formation, and prooxidant enzyme activity such as NADPH oxidase in various cell types such as VSMCs, endothelial cells, rat kidney mesangial cells, rat hepatocytes, platelets, SH-SY5Y neural cells. Incubation of VSMCs with 25 mM glucose or fructose for 3 h increases MG production 3.5 or 3.9 fold, respectively, and increases oxidative stress (Dhar et al., 2008). Excess superoxide anion so
formed can react with nitric oxide (NO) to form peroxynitrite which is a strong oxidant and nitrating agent (Takahashi et al., 2010; Dhar et al., 2008; Chen & Wu, 2008).

MG can also increase oxidative stress by reducing antioxidants such as glutathione peroxidase, glutathione reductase and GSH. Glutathione peroxidase detoxifies hydrogen peroxide to water with the help of GSH, which is converted to reduced glutathione and then back to GSH with the help of glutathione reductase. Thus, reduced availability of anti-oxidants impairs MG detoxification and begins a cycle which further causes oxidative damage (Blakytny and Harding, 1992; Paget, 1998). MG-modified albumin treatment in monocytes resulted in increased ROS production, thus suggesting that MG, by activating monocytes, induced apoptosis of neutrophils, caused platelet–neutrophil aggregation, then thrombosis and inflammation (Desai & Wu, 2008).

The major source of energy production and major site of ATP in the cells is the mitochondrion, which is also a major source of free radical generation especially superoxide anion. The intracellular superoxide anion is formed when single electrons escape the mitochondrial chain reaction, mainly from complex I and complex III and interact with molecular oxygen to form superoxide anion. In in vitro studies, MG has been shown to increase superoxide anion production. Rat aortic VSMCs treated with MG (30 µM) significantly increased superoxide anion production, which was prevented by the AGEs breaker, alagebrium (50 µM) (Chang et al., 2005; Wang et al., 2008b). Recently, we have shown that VSMCs and endothelial cells treated with MG (30 – 100 µM) for 24 h significantly increased ROS production in a time dependent manner which was prevented by arginine (Dhar et al., 2012).
MG induces oxidative stress through multiple mechanisms and pathways as shown in the figure.

Abbreviations: AGEs, advanced glycation end products; GSH, reduced glutathione; GSH-Px, glutathione peroxidase; GSH-Red, glutathione reductase; GSSG, oxidized glutathione; H₂O₂, hydrogen peroxide; ICAM-1, intercellular adhesion molecule-1; IFNγ, interferon γ; IL-1, interleukin-1; JNK, JUN N-terminal kinase; MG, methylglyoxal; NF-κB, nuclear factor-kappaB; NO, nitric oxide; O₂⁻, superoxide anion; ONOO⁻, peroxynitrite; p38 MAPK, p38 mitogen activated protein kinase; RAGE, receptor for advanced glycation endproduct; SOD, superoxide dismutase; VCAM 1, vascular cell adhesion molecule 1.
In *in vivo* studies the effect of MG on oxidative stress is associative. For example, we have shown that elevated plasma and aortic MG levels in the aorta of 13 week old SHR with elevated blood pressure is associated with increased superoxide anion levels and significantly reduced GSH levels, and glutathione peroxidase and glutathione reductase activities, compared to age-matched WKY rats. In diseases such as diabetes and hypertension, the elevation of MG levels is associated with increased oxidative stress (Wang *et al*., 2005). MG through AGEs formation can also cause oxidative stress. The excess of CEL, CML, and argpyrimidines formed by reaction of MG with lysine and arginine, are associated with oxidative stress. These AGEs and glycated proteins induce oxidative stress through production of cytokines and growth factors. Moreover, AGEs interact with the receptor for AGEs (RAGE) to induce oxidative stress in various cell types such as VSMCs, endothelial cells and phagocytes. AGE-RAGE interaction in the endothelial cells increases NF-κB activity to increase oxidative stress (Desai & Wu, 2008).

### 1.2. MG and Endothelial Dysfunction

L-arginine (L-Arg), but not D-arginine (D-Arg), is a substrate for nitric oxide synthase (NOS), which catalyzes the formation of nitric oxide (NO) and L-citrulline (Palmer *et al*., 1988). There are three isoforms of NOS, endothelial NOS (eNOS), inducible NOS (iNOS) and neuronal NOS (nNOS) (Moncada *et al*., 1991). eNOS is mainly found in the endothelial cells and mediates endothelium-dependent agonist induced vessel relaxation (Moncada *et al*., 1991). Reduced production or availability of NO is a common feature of endothelial dysfunction (De Vriese *et al*., 2000; Potenza *et al*., 2009), which is commonly defined as reduced endothelium-dependent vascular relaxation, and is a feature of aging, as well as diabetes, atherosclerosis.
hypertension and several other conditions (Berkowitz et al., 2003; Zhang et al., 2001). Arginase is an enzyme of the urea cycle that converts L-Arg, but not D-Arg, to urea and ornithine. There are two isoforms, arginase I and arginase II (Haraguchi et al., 1987; Morris et al., 1997). Arginases are expressed in the endothelium (Wei et al., 2000) and can cause endothelial dysfunction (Zhang et al., 2001; Berkowitz et al., 2003). High glucose (25 mM) has been shown to increase arginase I activity, but not protein expression, in bovine coronary endothelial cells, and arginase I is increased in the aorta of streptozotocin diabetic rats (Romero et al., 2008), causing endothelial dysfunction (Ishizaka et al., 2007; Romero et al., 2008).

We have recently shown that in cultured rat aortic and human umbilical vein endothelial cells MG and high glucose reduced basal and bradykinin-stimulated NO production, cyclic guanosine monophosphate levels, and serine-1177 phosphorylation and activity of eNOS without affecting threonine-495 and Akt phosphorylation, and total eNOS protein (Dhar et al., 2010b). Evidently, safe and specific MG scavengers have the potential to prevent several different pathological conditions such as endothelial dysfunction and AGEs formation. Currently, there is a lack of safe and specific MG scavengers. Several investigators have used different compounds as MG scavengers, which have other actions and thus are non-specific and can even produce toxicity. These compounds include aminoguanidine (Brownlee et al., 1986; Edelstein et al., 1992).
The figure (Fig 1-7) shows an endothelial cell and the adjacent VSMC. Stimulants like shear stress, bradykinin, insulin and vascular endothelial growth factor (VEGF) activate eNOS by causing an increase in intracellular calcium (Ca^{2+}) and produce NO from the substrate L-Arg. NO diffuses to the VSMC, activates soluble guanylate cyclase (sGC), increases cyclic guanosine monophosphate (cGMP), reduces intracellular calcium and causes relaxation (Evora and Nobre, 1999). Under pathological conditions like diabetes and hypertension, increased superoxide anion (O_2•-) is produced, mainly from NADPH oxidase, which reacts with NO and forms peroxynitrite. This in turn reduces the bioavailability of NO and causes endothelial dysfunction. Reduced eNOS activity can also cause reduced NO production (Endemann and Schiffrin, 2004).
1.2.g MG Scavengers

The MG scavengers available are also known as anti-MG or anti-AGE and are usually non-specific and have multiple effects, which limits their efficacy. Some of the common MG scavengers are aminoguanidine, metformin, N-acetyl cysteine, alagebrium and arginine.

Aminoguanidine

Aminoguanidine (AG) is the most commonly used MG scavenger and AGEs formation inhibitor (Brownlee et al., 1986). It reacts with the carbonyl group of glucose and prevents it from reacting with proteins and thus prevents AGEs formation. It also neutralizes reactive aldehydes such as MG, glyoxal and 3-DG which are the major precursors of AGEs formation, thus acting as a scavenger (Brownlee et al., 1986; Edelstein et al., 1992). Aminoguanidine is a hydrazine derivative like hydralazine and has many properties similar to hydrazine (Nilsson, 1999). AG is non-specific and besides acting as an AGEs inhibitor and MG scavenger it has other effects as well. AG prevents NO and MG production in the body by inhibiting NOS, which catalyzes the conversion of L-Arg to NO (Moncada et al., 1991), and SSAO, an enzyme which catalyzes the conversion of aminoacetone to MG, respectively. AG prevents deamination of diamines such as histamine by potently inhibiting diamine oxidase, thereby raising histamine concentration (Schuler 1952; Evy et al., 1956). AG increases the synthesis of polyamines by binding to the enzyme S-adenosylmethionine decarboxylase (Stjernborn & Persson, 1993). AG can cause vitamin B6 deficiency by binding to pyridoxal, leading to its adverse effects (Miyata & Van, 2003). AG has an inhibitory effect on AGEs formation as well as other mixed effects as shown in various in vitro and in vivo studies (Brownlee et al., 1986; Edelstein et al., 1992; Sajithlal et al., 1994; Conman et al., 1998). The in vivo dose of AG used in rodents ranges from
25 mg/kg/day (Brownlee et al., 1986; Seyer-Hansen et al., 1991) to 100 mg/kg/day (Inoue et al., 1998). Besides acting as an anti-oxidant in vitro, AG lowers total cholesterol, LDL and triglycerides in diabetic subjects. Studies have shown that AG reduces diabetes related complications like neuropathy, retinopathy and nephropathy in diabetic animal models. However, in clinical trials AG has shown safety concerns and unexpected results. In a clinical trial conducted on 690 patients with diabetic nephropathy, AG did not prevent the renal damage progression and did not show a statistically significant difference compared to the placebo group, apart from lowering serum creatinine (Bolton et al., 2004; Freedman et al., 1999). AG being like hydrazine, has many toxic effects. For example it may have effects like, antinuclear cytoplasmic antibody production, drug induced systemic lupus erythematosus and abnormal liver function. The patients treated with AG have flu-like symptoms, vasculitis and anaemia, thus limiting its therapeutic potential (Freedman et al., 1999). Moreover, AG through hydrogen peroxide formation in the presence of Fe$^{3+}$ can also cause DNA damage (Suji & Sivakami, 2006).

**Metformin**

Metformin is a commonly used drug for type 2 diabetes and comes under the class of biguanides. Chemically it is dimethylbiguanide and it is also a MG scavenger and AGEs formation inhibitor (Beisswenger et al., 1999). One study has shown that metformin scavenges MG by neutralizing it, via its guanidine group, which actually binds to MG and forms the inactive product triazepinone (Beisswenger & Ruggiero-Lopez, 2003; Ruggiero-Lopez et al., 1999; Baynes, 1991; Ota et al., 2007). Furthermore, metformin by increasing MG detoxification also reduces MG levels. Due to its MG scavenging effect, type 2 diabetes patients treated with high doses of metformin, ranging from 1,500 to 2,500 mg have significantly reduced MG levels.
(Beisswenger et al., 1999). We have also shown that SD rats fed with a high fructose diet have significantly high levels of MG in the plasma, hydrogen peroxide and MG-derived AGE, CEL, in the aorta, and high BP, which were attenuated by metformin (Wang et al., 2008) Also, in another study diabetic rats treated chronically with metformin had reduced AGEs formation in the lens, kidney and nerves (Tanaka et al., 1999). However, its use as a MG scavenger and AGEs inhibitor is limited due to its multiple effects, and it is currently used for type 2 diabetes as an insulin sensitizing drug.

N-acetyl cysteine

N-acetyl cysteine (NAC) is a well-known anti-oxidant and a MG scavenger (Millea, 2009; Vasdev et al., 1998). It is also known by other names such as acetylcysteine or N-acteyl-L-cysteine. NAC is the acetyl derivative of the amino acid cysteine, containing a thiol group, and MG has high binding affinity for cysteine (Vasdev et al., 1998; Lauterberg et al., 1983). NAC can also increase GSH levels (Lauterberg et al., 1983), the prime MG scavenger and antioxidant (Jia et al., 2006; Millea, 2009; Vasdev et al., 1998); thereby further acting as a MG scavenger and an anti-oxidant. It is also sold as a food supplement for protecting against liver abnormalities. It is clinically used in the management of acetaminophen overdose and cough (Millea, 2009; Lauterberg et al., 1983).

Alagebrium (ALA)

Alagebrium (ALA), also known formerly as ALT 711, is 4, 5-dimethylthiazolium (Wolffenbuttel et al., 1998) (Fig 1-8). ALA is an AGEs breaker and a MG scavenger. It acts as an AGEs breaker by breaking the covalent cross-links and thus is believed to be more important compared to AGEs inhibitors which are ineffective against formed AGEs (Desai & Wu, 2007).
ALA also causes reduction in oxidative stress and profibrotic cytokines (Susic et al., 2004). Moreover, AGEs induced oxidative stress is inhibited by ALA (Vasan et al., 2001). ALA has several beneficial actions on aging as well as on pathological conditions such as increased ventricular and arterial stiffness as observed in different animal models (Asif et al., 2000). ALA decreased ventricular stiffness and improved cardiac function in aged dogs treated with ALA for one month (Asif et al., 2000). ALA (10 mg/kg for 16 weeks) reduced oxidative stress and increased enzyme activity of glutathione peroxidase and superoxide dismutase in aging rats (Guo et al., 2009). Altered cardiac function was improved in older rhesus monkeys treated with ALA (Vaitkevicius et al., 2001). Clinical studies conducted on ALA showed it to be safe and revealed favourable results. ALA improved arterial compliance in a clinical study involving elderly patients with vessel stiffness, high systolic blood pressure and large artery compliance (Kass et al., 2001). In addition, other clinical studies showed that ALA reduced vascular fibrosis in elderly patients with systolic hypertension (Zieman et al., 2007) and decreased left ventricular mass in patients with diastolic heart failure (Little et al., 2005; Bakris et al., 2004).

![Chemical structure of alagebrium](image)

**Figure 1-8 Chemical structure of alagebrium.**
Increased DNA deletion, AGEs formation, reduced antioxidant capacity in aging heart and decreased superoxide dismutase activity and glutathione peroxidase activity in both aging heart and cardiomyocytes were all reversed on treatment with ALA, which also improved cardiac function (Guo et al., 2009). Furthermore, ALA does not inhibit thiamine diphosphokinase, which catalyses deamination of thiamine, and it therefore does not interfere with thiamine metabolism (Krautwald et al., 2011).

ALA also has acute preventive effect against MG as shown in our study in cells and SD rats. In SD rats administered MG (tested after 6 h exposure to MG), ALA significantly attenuated increased MG levels in the plasma and different organs and also attenuated MG-induced glucose intolerance. Moreover, ALA attenuated the increased MG levels in cells treated with MG, indicating its acute MG scavenging effect (Dhar et al., 2010).

Arginine

Arginine (Fig 1-9) is an amino acid and exists in two isomeric forms, L-Arg and D-Arg. L-arginine is a substrate for several enzymes including nitric oxide synthase (NOS), which converts it into NO and L-citrulline (Palmer et al., 1988). NO is a physiological mediator and a neurotransmitter with several physiological and pathological functions such as vascular and gastrointestinal smooth muscle relaxation, immune response, excessive vasodilation in septic shock etc (Moncada et al., 1991). The enzyme arginase uses L-arginine to produce ornithine and enable ammonia detoxification through the urea cycle (Haraguchi et al., 1987; Morris et al., 1997; Morris, 2009). L-arginine, along with glycine, is also converted by arginine:glycine amidinotransferase to ornithine and guanidinoacetate, the latter is then metabolized to creatine (Levillain, 2012; Van Pilsum et al., 1972). This helps with Na/K ATPase activity,
neurotransmitter release and other functions in the central nervous system. The enzyme arginine decarboxylase uses L-arginine as a substrate to produce agmatine, which is further converted to putrescine and urea by agmatinase (Satriano, 2003; Grillo & Colombatto, 2004). Thus, L-arginine is a part of several metabolic pathways.

L-arginine supplements have been reported to be useful in various conditions (Coman et al., 2008; Tapiero et al., 2002) including in preterm infants (Wu et al., 2004). It has been used for improving endothelium-dependent vasodilation in humans with hypercholesterolemia (Creager et al., 1992; Clarkson et al., 1996) and to lower the blood pressure in hypertension (Dong et al., 2011; Rajapakse et al., 2008). It was shown to reduce AGEs in diabetic rats (Pai et al., 2010). D-arginine has been reported to have no significant toxicity in mice besides having some non-specific effects (Navarro et al., 2005).

![Chemical structure of L-arginine.](image)

**Figure 1-9 Chemical structure of L-arginine.**

Due to its high affinity for MG, arginine can have great value as a safe MG scavenger. Since L-Arg is a substrate for 5 different enzymes, D-Arg can be a more specific and effective MG scavenger.
CHAPTER 2

HYPOTHESIS AND OBJECTIVES
2.1 Rationale for hypothesis

MG is a reactive aldehyde produced mainly from glucose and fructose in the body. Plasma MG levels are elevated in conditions of hyperglycemia. An excess of MG, not degraded by the glyoxalase enzymes, reacts with exposed arginine, lysine and cysteine residues of proteins and enzymes and causes pathology. An ongoing investigation of proteins, enzymes and other macromolecules modified by MG is revealing the pathological effects of excess MG. For example we have recently shown that treatment of cultured rat aortic and human umbilical vein endothelial cells with MG or high glucose reduces eNOS activity and causes endothelial dysfunction (Dhar et al., 2010b). We have also shown that administration of MG for 4 weeks as a continuous infusion by a subcutaneous minipump induces features of type 2 diabetes in male SD rats (Dhar et al., 2011).

Dr Wu’s lab investigated two animal models which have hypertension, the SHR and high fructose diet fed rats (Hwang et al., 1987), and found that the plasma and tissue levels of MG were significantly elevated by 2-4 fold in both of these animal models, compared to their respective control groups (Wang et al., 2005; Wang et al., 2008). However, elevated plasma and tissue levels of MG under hypertensive condition were associative findings in these studies and did not establish a cause-effect relationship. In order to establish a direct role of MG in causing hypertension, it is necessary to administer MG exogenously in healthy animals and observe its effect on the BP and on body systems known to regulate the BP such as the RAAS and the sympathetic nervous system. The in vivo effects of exogenously administered MG have not been studied to evaluate its role in the pathogenesis of hypertension. Based on this rationale I used exogenous administration of MG in normal male SD rats in this project. The results obtained by
exogenous administration of MG can be corroborated by studies in which endogenous production of MG is increased. One way of increasing endogenous MG production in the body is by feeding animals with a high carbohydrate diet, either a high glucose or a high fructose diet, both of which are known precursors of MG formation (Dhar et al., 2008). Moreover, high carbohydrate diet fed animals are known to develop hypertension (Hwang et al., 1987; Kaufman et al., 1991; Nakagawa et al., 2006; Sanchez-Lozada et al., 2007; Tom et al., 2011; Wang et al., 2008). Therefore, I also used high fructose diet fed male SD rats in my project to study the role of endogenous MG in hypertension and on the body systems regulating the BP such as the RAAS.

The effects of an exogenous or endogenous compound in the body can be additionally confirmed by the use of co-treatment with a known inhibitor of the compound, which should attenuate or prevent the effects of the compound. Studies involving MG become limited by lack of availability of specific MG scavengers. Some of the MG scavengers used by researchers include aminoguanidine (Brownlee et al., 1986; Edelstein et al., 1992), N-acetyl cysteine (Jia et al., 2006; Millea, 2009; Vasdev et al., 1998), metformin (Beisswenger et al., 1999; Beisswenger & Ruggiero-Lopez, 2003; Ruggiero-Lopez et al., 1999; Baynes, 1991; Ota et al., 2007) and alagebrium (Dhar et al., 2010). However, none of these are specific as MG scavengers, and aminoguanidine also has toxic effects (Freedman et al., 1999; Suji & Sivakami, 2006). One of the aims of my project was to identify a novel specific and safe MG scavenger. MG has great affinity for arginine (Takahashi, 1977; Lo TW et al., 1994). As discussed in the introduction, L-arginine is a substrate for at least five different enzymes in the body so it can have other effects when it is used as a MG scavenger. On the other hand D-arginine is not a substrate for
those enzymes and it may act specifically as a MG scavenger only with no or minimal other effects. It is also possible that L-arginine, besides scavenging MG can be an attractive oral supplement due to its reported beneficial effects on endothelial dysfunction and the BP (Creager et al., 1992; Clarkson et al., 1996; Dong et al., 2011; Rajapakse et al., 2008).

Based on the above rationale the following hypotheses were formed:

2.2 Hypotheses:

(i) A pathological elevation of methylglyoxal levels in the body, resulting from exogenous administration, or produced from a high fructose diet, upregulates the renin angiotensin aldosterone system and causes hypertension.

(ii) Arginine can scavenge methylglyoxal and attenuate its deleterious effects on endothelial function and oxidative stress.

2.3 Objectives and experimental approach:

2.3.a To investigate whether exogenous MG, administered by a continuous infusion for 4 weeks, is a causative factor in the pathogenesis of hypertension: A study of the underlying signaling pathways and molecular mechanisms in Sprague-Dawley rats and cultured cells.
I performed experiments to determine whether MG is one of the causative factors in the development of hypertension. Since the RAAS plays a major role in the regulation of BP, I focused my attention on the RAAS. Ang II acts on VSMC AT$_1$ receptors to cause vasoconstriction, therefore I also looked at the expression of AT$_1$ receptors. Since Ang II also facilitates peripheral noradrenergic neurotransmission and releases catecholamines from the adrenal medulla, I also determined the expression of adrenergic $\alpha_{1D}$ receptors.

The effects of MG, and alagebrium, a MG scavenger, on the RAAS and the BP were investigated in 12 week old male SD rats. SD rats were treated with a continuous infusion of MG with a subcutaneously implanted minipump for 4 weeks. Organs / tissues and cultured VSMCs were used for molecular studies. HPLC was used to measure MG levels, western blotting was used to measure proteins for adrenergic $\alpha_{1D}$ receptor, AT$_1$ receptor, angiotensin, renin, Erk 1/2 (p-Erk 1/2), NFATc and NFkB. Q-PCR was used to measure mRNA levels for $\alpha_{1D}$ receptor, AT$_1$ receptor, angiotensin and renin in cultured cells, kidney and aorta of MG treated rats. Possible mechanisms were explored through gene silencing of angiotensinogen and RAGE.

2.3.b To investigate the effects of a high fructose diet, a precursor for MG formation, on the pathogenesis of hypertension and its attenuation by a MG scavenger: A study of the underlying signaling pathways and molecular mechanisms in Sprague-Dawley rats.

High fructose corn syrup and sugar are the main ingredients of a high carbohydrate diet, which is believed to be the root cause of the current epidemic of obesity, type 2 diabetes and the associated cardiovascular pathology. The aim of my study was to investigate whether MG is a
mediator of fructose-induced hypertension and the underlying molecular mechanisms, since fructose is a known precursor of MG generation (Dhar et al., 2008). Male SD rats were treated with a high fructose diet (60% of total calories) for 16 weeks. The thoracic aorta and cultured VSMCs were used to study the signaling pathways and the molecular mechanisms. HPLC was used to measure MG and GSH levels, western blotting was used to measure proteins for adrenergic α1D receptor, AT1 receptor, angiotensin, renin, Erk 1/2 (p-Erk 1/2) and NFATc. Q-PCR was used to measure mRNA levels for α1D receptor, AT1 receptor, angiotensin, renin in the kidney and the aorta of fructose treated rats.

2.3.c To investigate whether arginine can attenuate methylglyoxal- and high glucose-induced endothelial dysfunction and oxidative stress in rat isolated aortic rings and cultured cells.

Specific and safe MG scavengers are not available. Since MG has great affinity for arginine (Takahashi, 1977; Lo TW et al., 1994), I investigated whether L-arginine and D-arginine can attenuate MG and high glucose-induced endothelial dysfunction and oxidative stress. Aortic rings isolated from 12 week old male SD rats were used for contractility studies. Cultured human umbilical vein endothelial cells (HUVECs) and VSMCs were used to define molecular pathways and mechanisms. HPLC was used to measure MG levels and western blotting was used to measure proteins for NF-κB, NADPH oxidase 4, arginase I and II. Dichlorofluorescein (DCF) probe was used to measure oxidative stress. Immunostaining was used to measure MG-induced AGE (CEL).
CHAPTER 3

GENERAL METHODOLOGY
3.1 Animals

Male 11-week old Sprague-Dawley rats from Charles River Laboratories (Saint-Constant, Quebec, Canada) were used according to a protocol approved by the Animal Care Committee at The University of Saskatchewan, following guidelines of the Canadian Council on Animal Care. After one week of acclimatization, the rats were anesthetized with an inhalation of isoflurane (Forane, 4% in oxygen), delivered through a precision vaporizer and circle absorption breathing system (Ohio, 30/70 Proportioner Anesthesia Machine, Madison, Wisconsin). When anesthesia reached sufficient depth as determined by the absence of the leg flexor response and the eyelid reflex, the thorax was quickly opened by a midline incision and the rat was killed by cutting open the heart and causing exsanguination, an accepted method of euthanasia by the Animal Care Committee. The aorta was quickly removed without damaging the endothelium and placed in a beaker filled with Kreb’s solution and bubbled with 95% O₂ + 5% CO₂.

In one separate batch of 28 male 12 week old SD rats a subcutaneous mini-osmotic pump (Alzet® 2ML4) (Durect Corporation, Cupertino, CA, USA) was implanted to deliver either saline (0.9%) or MG (24 mg/day) by continuous infusion for 28 days. The rats were randomly divided into the following treatment groups (n = 7 in each group): 1. Control (0.9% saline by pump), 2. MG (24 mg/day by pump), 3. MG + alagebrium (ALA, 30 mg/kg/day in drinking water), 4. ALA (30 mg/kg/d in drinking water) + 0.9% saline by pump. In a second batch of 24 male 12 week old Sprague-Dawley rats a different MG scavenger, aminoguanidine, had to be used due to unavailability of ALA. The following treatments were provided to 4 groups (n = 6 each): 1. Control (0.9% saline by pump), 2. MG (24 mg/day by pump), 3. MG + aminoguanidine
(AG, 100 mg/kg/day in drinking water), 4. AG (100 mg/kg/d in drinking water) + 0.9% saline by pump

For high fructose diet study 32 male 5 week old Sprague-Dawley rats were divided into the following groups \((n = 8\) in each group): 1. Control chow, 2. High fructose (60% in diet), 3. High fructose + metformin (500 mg/kg/day in drinking water), 4. Metformin (500 mg/kg/day in drinking water + control chow). The treatments were for 16 weeks.

At the end of study fructose treated (16 weeks) and MG pump treated (28 days) rats were anaesthetized with sodium pentobarbital (60 mg/kg body weight) which was given intraperitoneally. BP was again measured by carotid artery cannulation for 30 min. Blood was collected from the carotid artery and plasma was separated from the samples after centrifugation at 12,000 g for 10 min at 4°C. Tissues cleaned in ice-cold phosphate buffer saline were immediately frozen in liquid nitrogen and stored at -80°C until processing.

### 3.2 Cell culture

Rat thoracic aortic smooth muscle cell line (A-10 cells) was obtained from American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal bovine serum (FBS) at 37°C in a humidified atmosphere of 95% air and 5% CO\(_2\), as described in previous studies from our lab (Dhar et al., 2008). A-10 cells were seeded either in 100 mm dishes for MG measurement or in 96-well plates for other assays, with an equal amount of cells \((10^6/mL)\) in each well, and cultured to confluence. For immunocytochemistry staining, cells were seeded on cover glass slides \((2\times10^6/mL)\). Cells were starved in FBS-free DMEM for 24 h before exposure to different metabolic precursors.
Human umbilical vein endothelial cells from American Type Culture Collection (ATCC, Manassas, VA, USA) were cultured in Kaighn’s F12K medium containing 10% fetal bovine serum (FBS), 0.1 mg/mL heparin and 0.03-0.05 mg/mL endothelial cell growth supplement (Dhar et al., 2010b).

3.3 Methyglyoxal assay

MG was measured by a specific and sensitive HPLC method as described previously (Dhar et al., 2009). MG was derivatized with o-phenylenediamine (o-PD) to specifically form 2-methylquinoxaline. The samples were incubated in the dark for 24 h with 0.45 N perchloric acid (PCA) and 10 mM o-PD at room temperature. Samples were centrifuged at 12000 rpm for 10 min. 2-methylquinoxaline and quinoxaline internal standard (5-methylquinoxaline) were quantified on a Hitachi D-7000 HPLC system (Hitachi, Ltd., Mississauga, ON, Canada) via Nova-Pak® C18 column (3.9×150 mm, and 4 μm particle diameter, Waters Corporation, Milford, MA, USA) (Dhar et al., 2009).

3.4 Western blotting

Cell lysates were prepared as described earlier (Dhar et al., 2010b; Dhar et al., 2011) and the protein concentration in the supernatant was determined by the BCA protein assay (Sigma-Aldrich Canada Co., Oakville, ON, Canada). Aliquots of cell lysates (40-50 μg of protein each) were separated on 6-10% SDS-PAGE, electrotransferred to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad Laboratories Canada Ltd., Mississauga, ON, Canada), blocked with 5% nonfat milk in TBS-Tween buffer for 2 h at room temperature, and incubated overnight at 4°C.
with the primary antibodies to arginase I, arginase II, NADPH oxidase 4 (NOX4), AT₁ receptor (AT₁R), α₁D receptor (α₁D), renin, angiotensin, ACE, (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), receptor for AGEs (RAGE), nuclear factor κB (NF-κB) (Abcam, Cambridge, MA, USA), and anti-β-actin (diluted 1:1000) (Sigma-Aldrich Canada Ltd., Mississauga, ON, Canada) followed by incubation with horse radish peroxidase conjugated secondary antibodies (Life Science, Hercules, CA, USA) (diluted 1:3000) for 2 h at room temperature and then with horseradish peroxidase conjugated secondary antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) for 1 h at room temperature. After extensive washing, the immunoreactive proteins were detected with an Enhanced Chemiluminescence Detection System (ECL; Amersham Biosciences Corp., Piscataway, NJ, USA) (Dhar et al., 2010b; Dhar et al., 2011).

3.5 Real time Quantitative PCR (RT-PCR)

Total RNA from the cultured cells, kidney and aorta was isolated using RNA isolation kit (Qiagen, Germantown, MD, USA). The pre-designed primers for angiotensin, AT₁R, α₁D, renin, aldosterone receptor (MR) and RAGE were purchased from Qiagen, (Germantown, MD, USA). The real-time PCR was performed in an iCycler iQ apparatus (Life Science, Hercules, CA, USA) associated with the ICYCLER OPTICAL SYSTEM software (version 3.1) using SYBR Green PCR Master Mix (Bio-Rad Laboratories Canada Ltd., Mississauga, ON, Canada).

3.6 Arginase activity assay

Arginase activity was measured using an arginase assay kit (BioAssay Systems, Hayward, CA, USA). Arginase catalyses the conversion of arginine to ornithine and urea.
Briefly cell lysates were mixed with substrate arginine buffer and incubated for 2 h. Urea reagent was added to stop the reaction and optical density (OD) was measured at 430 nm.

3.7 Measurement of reactive oxygen species

Confluent cells were loaded with a membrane-permeable, nonfluorescent probe 2′,7′-dichlorofluorescin diacetate (CM-H2DCFDA, 5 μM) for 2 h at 37° C in FBS-free medium in the dark. The cells treated with MG (30 μM) or glucose (25 mM) for 24 h were assayed for fluorescent oxidized dichlorofluorescein (DCF) as an indicator of production of ROS as described earlier (Dhar et al., 2008; Dhar et al., 2010b). The protein content of the homogenate was measured by BCA Protein assay (Bio-Rad, Hercules, CA, USA).

3.8 Immunocytochemistry

A-10 cells were seeded on glass cover slips followed by incubation with different test compounds for 24 h, and subjected to staining for the MG-induced AGE, Nε-carboxyethyl lysine (CEL). As described previously (Dhar et al., 2008; Dhar et al., 2011), the treated cells were fixed in 4% paraformaldehyde for 30 min at room temperature and washed twice with 0.01 N phosphate buffered saline (PBS). After permeation with 0.1% Triton X-100 for 5 min and two washes with PBS, the cells were incubated with normal goat serum (diluted 1:30 in 0.1 N PBS) for 1 h to block non-specific binding sites. After shaking off the goat serum the slides were incubated with the CEL antibody (1:100; a generous gift from Novo Nordisk, A/S, Denmark) overnight at room temperature. Cells were washed twice in PBS (0.01 N) for 5 min and incubated with secondary fluorescein isothiocyanate (FITC) conjugated anti-CEL antibody.
(Molecular Probes) for 2 h. After washing thrice with PBS the slides were mounted in glycerol:PBS (3:7), coverslipped and observed under a fluorescence microscope. Staining intensity was quantified using the Metamorph image analysis software (v. 7, Molecular Devices). Slides from four different experiments were analyzed with 5 fields per slide observed and averaged.

3.9 Isometric tension studies on aortic rings

A group of 24 SD rats was used. Isometric tension studies were carried out on rat aortic rings as described (Dhar et al., 2010b). Briefly, 3-4 mm thoracic aortic rings from the rat aorta were mounted under a 2 g load in four separate 10 mL organ baths containing Krebs solution with 5 mM glucose, maintained at 37° C and bubbled with 95% O₂ + 5% CO₂. After a 90 min equilibration period the rings were pre-contracted with phenylephrine (1 µM) and cumulative concentration-dependent relaxation in response to acetylcholine (ACh) was obtained before (Control) and 2 h after incubation with either glucose (25 mM) or MG (100 μM) (Dhar et al., 2010b), or the nitric oxide synthase inhibitor, Nω-nitro-L-arginine methyl ester (L-NAME, 10 µM). In initial experiments the responses to ACh were repeated before and 2 h after incubation with normal Krebs solution to confirm reproducibility of responses to ACh. Some sets of rings were co-incubated with either L-Arg (300 µM) or D-Arg (300 µM) for 2 h. Treatment with each compound was tested in rings from at least 5 different rats. Isometric tension was measured with isometric force transducers with the ‘Chart’ software and Powerlab equipment (AD Instruments Inc., Colorado Springs, CO, USA).
3.10 Plasma assays

Assay kits for quantitative determination of plasma renin (AnaSpec, Fremont, CA, USA), angiotensin II (Biovendor LLC, Candler, NC, USA), aldosterone (Cayman Chemical Co., Ann Arbor, MI, USA), and catecholamines (Rocky Mountain Diagnostics Inc., Colorado Springs, CO, USA) were used according to the manufacturer’s instructions.

3.11 Short interfering (siRNA) transfection

In a six well tissue culture plate, 2 x 10⁵ cells per well were grown in 2 mL antibiotic-free normal growth medium supplemented with FBS. Cells were incubated at 37° C in a CO₂ incubator until 60-80% confluent. For each transfection, 2-8 μL of siRNA duplex (Solution A, 0.25-1 μg or 20-80 pmols siRNA) was diluted with 100 μL siRNA transfection medium (Cat # sc-36868, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). For each transfection, 2-8 μL of siRNA transfection reagent (Solution B, Cat # sc-29528, Santa Cruz Biotechnology Inc.) was diluted with 100 μL siRNA transfection medium (Cat # sc-36868). siRNA duplex solution (Solution A) was directly added to the dilute transfection reagent (Solution B) using a pipette. The solution was mixed gently by pipetting up and down, following which it was incubated for 15-45 min at room temperature. The cells were washed once with 2 mL of siRNA transfection medium (Cat # sc-36868). For each transfection, 0.8 mL siRNA transfection medium was added to each tube containing the siRNA transfection reagent mixture (Solution A + Solution B). After gentle mixing the mixture was added to the washed cells, and incubated for 5-7 h at 37° C in a CO₂ incubator. After the required incubation, 1 mL of normal growth medium containing 2 times the normal serum and antibiotics concentration (2x normal growth medium) was added without
removing the transfection mixture. The cells were additionally incubated for another 18-24 h. After 24 h, the medium was aspirated and replaced with fresh 1x normal growth medium. The cells were assayed 48-72 h later after the addition of fresh medium.

3.12 Measurement of reduced glutathione (GSH)

The reduced glutathione (GSH) levels in tissues was determined by derivation with 5, 5'-dithio-bis (2-nitrobenzoic acid), and reverse-phase HPLC using ultra-violet detection (Kamencic et al., 2000). An equal volume of 10% 5-sulfosalicylic acid containing 0.2 mM EDTA was added to the tissue or cell homogenate to precipitate the proteins. After centrifugation at 10,000 g for 15 min the supernatants were collected for GSH analysis. The reaction mixture was made by mixing 0.5 mL 50 mM Tris–HCl buffer (pH 8.9), 0.13 mL sample or standard, 0.02 mL internal standard [400 μM D(2)-penicillamine in cold 5% sulfosalicylic acid containing 0.1 mM EDTA], and 0.35 mL 10 mM 5,5-dithiobis(2-nitrobenzoic acid) made in 0.5 mM K$_2$HPO$_4$ (pH 7.2). After 5 min incubation, the mixture was acidified with 0.05 mL 7 M H$_3$PO$_4$. 50 μl of the mixture was injected for elution at 37°C using a Hitachi D-7000 HPLC system (Hitachi, Ltd., Mississauga, ON, Canada) via Nova-Pak® C18 column (150 x 4.6 mm, 4 μm particle diameter, Waters Corporation, Milford, MA, USA). The mobile phase was made by mixing 12.5% methanol (v/v) and 100 mM KH$_2$PO$_4$ (pH 3.85). The flow rate was set at 1.1 mL/min. Sulphydril–DTNB derivatives were detected by ultraviolet absorbance at 330 nm. Standards contained L-cysteine, cysteinyly glycine, glutathione, and DL-homocysteine.
Publications and their relation to the thesis

The results of this thesis have been published as three manuscripts.

Chapter 4 describes the effects of exogenously administered MG on the RAAS and BP. These experiments were carried out to investigate our hypothesis (i) that a pathological elevation of MG, administered exogenously or produced from a high fructose diet in the body, causes hypertension. The experimental protocols were designed in accordance with objective 2.2.a described in chapter 2. The roles of the authors listed in this manuscript were as follows: Indu Dhar – I performed all the experiments, helped to design the experimental protocols and suggested some ideas to the supervisor. I wrote the first draft of the manuscript and revised the manuscript as suggested by the supervisor, co-supervisor and peer reviewers. Arti Dhar – a senior graduate student and a postdoctoral fellow taught me some of the techniques and supervised me in the lab at the beginning. Lingyun Wu – my co-supervisor suggested some ideas, and provided critical inputs towards my work, manuscript and discussions. Kaushik Desai – my supervisor suggested the idea for the work and provided critical inputs towards my work, manuscript and discussions.

Chapter 5 describes the effects of a high fructose diet and the role of endogenously produced MG on the RAAS and BP. These experiments were carried out to investigate our hypothesis (i) that a pathological elevation of methylglyoxal, administered exogenously or produced from a high fructose diet in the body, causes hypertension. After showing the role of exogenous MG in up regulating the RAAS and increasing the BP, the next logical step was to see if endogenously produced MG had similar effects on the RAAS and the BP, as exogenously
administered MG. Fructose is a precursor for MG formation (Dhar et al., 2008) and a major component of the high carbohydrate diets in humans. High fructose diet is believed to be responsible for the current epidemic of type 2 diabetes and the associated cardiovascular conditions (Johnson et al., 2007; Selvaraju et al., 2012; Stanhope, 2012). Therefore, rats were fed a high fructose diet, which has been shown previously to generate increased MG (Wang et al., 2008). The experimental protocols were designed in accordance with objective 2.2.b described in chapter 2. The roles of the authors listed in this manuscript were as follows: Indu Dhar – I performed all the experiments, helped to design the experimental protocols and suggested some ideas to the supervisor. I wrote the first draft of the manuscript and revised the manuscript as suggested by the supervisor, co-supervisor and peer reviewers. Arti Dhar – a senior graduate student and a postdoctoral fellow taught me some of the techniques, and reviewed and suggested corrections for my manuscript. Lingyun Wu – my co-supervisor suggested some ideas, and provided critical inputs towards my work, manuscript and discussions. Kaushik Desai – my supervisor suggested the idea for the work and provided critical inputs towards my work, manuscript and discussions.

Chapter 6 describes the effects of arginine in preventing or attenuating the deleterious effects of MG. These experiments were carried out to investigate our hypothesis (ii) that arginine can scavenge MG and attenuate its deleterious effects on endothelial function and oxidative stress. One major problem we encountered in our project work was finding a specific, safe and effective MG scavenger to prevent its harmful effects. One of the principles of pharmacological experiments is to demonstrate that effects of a given agent A can be prevented by another agent B, which can be a specific antagonist, or a scavenger of agent A. This strategy is used to
establish a cause effect relationship and to discover new drugs. Since there are no safe and specific MG scavengers our intention was to determine whether arginine, an amino acid and a commonly used nutritional supplement, can act as an effective MG scavenger. This idea was based on the known affinity of arginine for MG (Takahashi, 1977). The experimental protocols were designed in accordance with objective 2.2.c described in chapter 2. The roles of the authors listed in this manuscript were as follows: Indu Dhar – I performed all the experiments and helped to design the experimental protocols. I wrote the first draft of the manuscript and revised the manuscript as suggested by the supervisor, co-supervisor and peer reviewers. Arti Dhar – a senior graduate student and a postdoctoral fellow taught me some of the techniques including isolated aortic ring experiments, and reviewed and suggested corrections for my manuscript. Lingyun Wu – my co-supervisor suggested some ideas, and provided critical inputs towards my work, manuscript and discussions. Kaushik Desai – my supervisor suggested the idea for the work and provided critical inputs towards my work, manuscript and discussions.
CHAPTER 4

Methylglyoxal, a reactive glucose metabolite, increases renin angiotensin aldosterone and blood pressure in male Sprague-Dawley rats

Indu Dhar, Arti Dhar, Lingyun Wu*, Kaushik M Desai*

ID, AD, KD: Department of Pharmacology, College of Medicine, University of Saskatchewan, Saskatoon, Canada

LW: Department of Health Sciences, Lakehead University, Thunder Bay, Canada & Thunder Bay Regional Research Institute, Thunder Bay, ON, Canada

This chapter is “In Press” (DOI: 10.1093/ajh/hpt281) to be published soon in the American Journal of Hypertension

Running title: Methylglyoxal and renin angiotensin system

Non-standard abbreviations: AGEs - advanced glycation endproducts; ALA – alagebrium; Erk 1/2 - extracellular signal related kinases 1/2; MG – methylglyoxal; NF-κB - nuclear factor kappa B; RAAS - renin angiotensin aldosterone system; RAGE - receptor for AGEs; VSMCs - vascular smooth muscle cells
4.1 Abstract

The majority of people with diabetes develop hypertension, along with increased activity of the renin angiotensin system. Methylglyoxal, a reactive glucose metabolite, is elevated in diabetic patients. We investigated the effects of methylglyoxal, and alagebrium, a methylglyoxal scavenger, on the renin angiotensin system and blood pressure. Male Sprague-Dawley rats were treated with a continuous infusion of methylglyoxal with a minipump for 4 weeks. Organs / tissues and cultured vascular smooth muscle cells (VSMCs) were used for molecular studies. HPLC, Western blotting and Q-PCR were used to measure methylglyoxal, proteins and mRNA, respectively. siRNA for angiotensinogen and the receptor for advanced glycation endproducts (RAGE) were used to study mechanisms. Methylglyoxal treated rats developed a significant increase in blood pressure and plasma levels of aldosterone, renin, angiotensin and catecholamines. Methylglyoxal level, and protein and mRNA for angiotensin, AT₁ receptor, adrenergic α₁D receptor and renin were significantly increased in the aorta and/or kidney of methylglyoxal treated rats, a novel finding. Alagebrium attenuated the above effects of methylglyoxal. Treatment of cultured VSMCs with methylglyoxal or high glucose (25mM) significantly increased cellular methylglyoxal, and protein and mRNA for NF-κB, angiotensin, AT₁ and α₁D receptors, which were prevented by inhibition of NF-κB, and by alagebrium. Silencing of mRNA for RAGE prevented the increase in NF-κB induced by methylglyoxal. Silencing of mRNA for angiotensinogen prevented the increase in NF-κB, angiotensin, AT₁ and α₁D receptors’ protein. Methylglyoxal activates NF-κB through RAGE and thereby increases renin angiotensin levels, a novel finding, and a probable mechanism of increase in blood pressure.
4.2 Introduction

Type 2 diabetes and hypertension are major global health issues. Two-thirds of the people with diabetes have hypertension [blood pressure (BP): systolic $\geq 140$ mmHg or diastolic $\geq 90$ mmHg] (Ferrannini et al., 2012). The mechanism of the pathogenesis of hypertension in diabetes is not well established. The renin-angiotensin aldosterone system (RAAS) plays a major role in maintaining fluid balance, vascular tone and BP (Crowley et al., 2012; Fournier et al., 2012). Angiotensin II (Ang II) also increases activity of the sympathetic nervous system (Crowley et al., 2012). Increased activity of the RAAS is seen in type 2 diabetics with hypertension (Hsueh et al., 2011). Increased activity of the RAAS has also been proposed to be one of the etiologic factors for type 2 diabetes mellitus (Goossens, 2012; Luther et al., 2011; Zhou et al., 2012).

Glucose is one of the main precursors for the formation of methylglyoxal (MG), a reactive aldehyde (Cooper et al., 1970; Dhar et al., 2008). Normally, MG is rapidly degraded mainly by the glyoxalase enzymes with the help of reduced glutathione (GSH) (Cooper, 1984). In conditions of excess MG formation, such as hyperglycemia, the glyoxalase enzymes get overwhelmed and the excess MG reacts with other proteins and enzymes and disrupts their normal function (Vander Jagt et al., 2003). Plasma MG levels are elevated in people with diabetes (McLellan et al., 1994; Wang et al., 2007a). We have recently shown that administration of MG for 4 weeks as a continuous infusion by a subcutaneous minipump induces features of type 2 diabetes in Sprague-Dawley rats (Dhar et al., 2011). MG is a major precursor for the formation of advanced glycation endproducts (AGEs) (Ahmed et al., 1997; Vander Jagt et al., 2003). MG causes increased oxidative stress (Desai et al., 2008; Wu et al., 2002), which in turn is believed to cause the pathophysiological changes in diabetes, hypertension, and aging.
(Ceriello, 2008; Ceriello et al., 2004; Harman, 1998). For example, MG activates nuclear factor kappa B p65 (NF-κB p65), and inactivates antioxidant enzymes like glutathione reductase and glutathione peroxidase, in rat vascular smooth muscle cells (VSMCs), and causes oxidative stress (Wu et al., 2002). On the other hand increased oxidative stress can deplete GSH and slow down degradation of MG, thereby increasing its levels and harmful effects (Desai et al., 2008; Vander Jagt et al., 2003). Specific and safe scavengers of MG will have great therapeutic value to prevent hyperglycemia and high carbohydrate diet-induced pathology resulting from excess MG formation. Elevated plasma levels of MG have been reported in spontaneously hypertensive rats and fructose-fed rats (Wang et al., 2005; Wang et al., 2008), but it is not yet known whether MG is the cause or effect of hypertension. We hypothesized that MG upregulates the RAAS and increases BP in rats, as the basis of the work reported here.

4.3 Methods

Animals

Male Sprague-Dawley rats from Charles River Laboratories (Quebec, Canada) were used according to guidelines of the Canadian Council on Animal Care. All animal protocols were approved by the University of Saskatchewan’s Animal Research Ethics Board. 28 male 12 week old Sprague-Dawley rats with closely matching body weights were used. A miniosmotic pump (Alzet® 2ML4, Durect Corp., Cupertino, CA, USA) was surgically implanted subcutaneously on the back under sterile conditions (Dhar et al., 2011). This pump holds a fixed volume (2 mL) of drug and releases a continuous small amount of MG (40% solution, Sigma-Aldrich Canada Ltd., Oakville, ON, Canada) into the body at a rate of 1 mg/h or 24 mg/day or 672 mg over 28 days.
Hence each rat received a fixed dose (24 mg/day) and therefore it is not expressed as mg/kg. To control for this fixed dose the rats were from the same batch, of the same age and similar in weight. We have successfully used this minipump previously to deliver MG to rats for 28 days (Dhar et al., 2011). Pumps were implanted in all rats to deliver either MG or normal saline (0.9% NaCl). Anesthesia was provided by a continuously monitored inhalation of isoflurane (Forane) (2-4%) in oxygen, delivered through a precision vaporizer and circle absorption breathing system (Ohio, 30/70 Proportioner Anesthesia Machine, Madison, Wisconsin), with the rat placed on a heated pad to maintain a rectal temperature of 37°C. Buprenorphine injection (0.025 mg/kg s.c. twice a day) was used as a preanesthetic and post-surgical recovery analgesic for two days following implantation.

The rats were divided into the following treatment groups (n = 7 each): 1. Control (0.9% saline by pump), 2. MG (24 mg/day by pump), 3. MG + alagebrium (ALA, a MG scavenger (Dhar et al., 2010a), 30 mg/kg/day in drinking water), 4. ALA + 0.9% saline by pump. At the end of the study, the rats were anaesthetized with sodium pentobarbital (60 mg/kg body weight, i.p.). After 15 min stabilization the BP was measured by carotid- artery cannulation for 30 min (Desai et al., 2006; Laight et al., 2000). Blood was collected from the carotid artery and plasma was separated and stored at -80°C. Organs / tissues cleaned in ice-cold phosphate buffer saline were immediately frozen in liquid nitrogen and stored at -80°C until processing.

**Biochemical assays**

Assay kits for quantitative determination of plasma renin (AnaSpec, Fremont, CA, USA), angiotensin (Cayman Chemicals, Ann Arbor, USA), aldosterone (Cayman Chemical Co.,
Ann Arbor, MI, USA) and catecholamines (Rocky Mountain Diagnostics, Inc., Colorado Springs, CO, USA) were used according to the manufacturer’s instructions.

**Cell culture**

Rat thoracic aortic smooth muscle cells (A-10 cells, CRL-1476, American Type Culture Collection, Manassas, VA, USA) were cultured as described previously (Dhar et al., 2008). The cells were seeded either in 100 mm dishes for MG measurement or 6 well plates for other assays, with an equal amount of cells (10⁶/mL) in each well, and cultured to confluence. Cells were starved in FBS-free DMEM medium for 24 h prior to exposure to different treatments alone or in combination: MG (30 μM based on preliminary results), glucose (5, 25 mM, based on preliminary results), ALA (100 μM) and a specific NF-κB inhibitor, CAY10512 (0.1 μM) (Cayman Chemical Co., Ann Arbor, MI, USA).

**Methylglyoxal measurement**

MG was measured by a specific and sensitive high-performance liquid chromatography (HPLC) method (Dhar et al., 2009). MG was derivatized with o-phenylenediamine to form the quinoxaline, 2-methylquinoxaline, which is very specific for MG. The 2-methylquinoxaline and the internal standard 5-methylquinoxaline were quantified on a Hitachi D-7000 HPLC system (Hitachi, Ltd., Mississauga, ON, Canada) via a Symmetry C18 column (3.9 x 150 mm, and 4 μm particle diameter; Waters, Milford, MA, USA).

**Western blotting**

61
Total proteins from cultured cells, aortic tissue and kidney were subjected to Western blot analysis as previously described (Dhar et al., 2011; Dhar et al., 2012). The following primary antibodies were used: Ang II AT$_1$ receptor (AT$_1$R), adrenergic $\alpha_{1D}$ receptor ($\alpha_{1D}$R), renin, angiotensin, angiotensin converting enzyme (ACE) (all from Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), receptor for advanced glycation endproducts (RAGE), nuclear factor $\kappa$B (NF-$\kappa$B) (Abcam, Cambridge, MA, USA), and anti-\$\beta$-actin (diluted 1:1000) (Sigma-Aldrich Canada Ltd., Mississauga, ON, Canada). Horse radish peroxidase conjugated secondary antibodies (Life Science, Hercules, CA, USA) (diluted 1:3000) were used. The proteins were visualized with ECL chemiluminescence reagent (GE Healthcare Life Sciences, Pittsburgh, PA, USA) and captured on X-ray film (GE Healthcare Life Sciences, Pittsburgh, PA, USA) (Dhar et al., 2011).

**Real time quantitative PCR (RT-PCR)**

Total RNA from the cultured cells, kidney and aorta was isolated using RNA isolation kit (Qiagen, Germantown, MD, USA) (Dhar et al., 2011). The pre-designed primers for angiotensin, AT$_1$R, $\alpha_{1D}$R, renin, aldosterone receptor (MR) and RAGE were purchased from Qiagen (Germantown, MD, USA). The real-time PCR was performed in an iCycler iQ apparatus (Life Science, Hercules, CA, USA) associated with the ICYCLER OPTICAL SYSTEM software (version 3.1) using SYBR Green PCR Master Mix (Bio-Rad Laboratories Ltd., Mississauga, ON, Canada) as previously described (Dhar et al., 2011).

**siRNA transfection for RAGE and angiotensinogen**
In a six well cell culture plate, 2 x 10^5 cells per well were grown in 2 mL antibiotic-free normal growth medium supplemented with FBS. The cells were incubated at 37° C in an incubator until 60-80% confluent. For each transfection, 2-8 μL of siRNA duplex (Solution A, 0.25-1 μg or 20-80 pmols siRNA) was diluted with 100 μL siRNA transfection medium (Cat # sc-36868, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). For each transfection, 2-8 μL of siRNA transfection reagent (Solution B, Cat # sc-29528, Santa Cruz Biotechnology Inc.) was diluted with 100 μL siRNA transfection medium (Cat # sc-36868). siRNA duplex solution (Solution A) was directly added to the dilute transfection reagent (Solution B) and mixed by pipetting the solution up and down, and incubated for 15-45 min at room temperature. The cells were washed once with 2 mL of siRNA transfection medium (Cat # sc-36868). For each transfection, 0.8 mL siRNA transfection medium was added to the siRNA transfection reagent mixture (Solution A + Solution B), mixed gently and added to the washed cells. The cells were incubated for 5-7 h at 37° C, followed by addition of 1 mL of normal growth medium containing 2 times the normal serum and antibiotics concentration, to the transfection mixture. The cells were incubated further for 18-24 h. The medium was aspirated and replaced with fresh 1x normal growth medium and the cells were assayed 48-72 h later.

**Materials**

Glucose, methylglyoxal and other reagents were purchased from Sigma Aldrich Canada Ltd. (Mississauga, ON, Canada) or VWR International (Mississauga, ON, Canada). Alagebrium (previously known as ALT-711, N-phenacyl-4,5-dimethyl-1,3-thiazolium) was a generous gift
from Synvista Therapeutics Inc. (Montvale, NJ, USA) (formerly Alteon Corp.). Synvista ceased operations in 2009 (BioSpace, 2009).

Statistical analysis

Data obtained from separate experiments are expressed as mean ± SEM. Statistical analysis was performed using ANOVA with post hoc Bonferroni’s test. A P value of less than 0.05 was considered to be statistically significant.

4.4 Results

Acute or chronic methylglyoxal treatment increases cellular, aortic and renal methylglyoxal levels

Incubation of cultured VSMCs for 24 h or 5 days with MG (30 µM) or high glucose (25 mM) caused a significant elevation of cellular MG that was attenuated by co-incubation with the MG scavenger ALA (Fig. 4-1A, B). Treatment of SD rats for 4 weeks with MG caused a significant increase in aortic and renal MG levels which was attenuated by co-treatment with ALA (Fig. 4-1C, D).

Chronic methylglyoxal treatment increases blood pressure and plasma catecholamines, renin, angiotensin and aldosterone levels

Treatment of SD rats for 4 weeks with MG caused a significant increase in the BP which was attenuated by the MG scavenger ALA (Fig. 4-2A). ALA alone did not affect the BP. Chronic MG treatment also caused a significant increase in plasma norepinephrine, epinephrine,
dopamine (Fig. 4-2B), angiotensin (Fig. 4-2C), renin (Fig. 4-2D) and aldosterone (Fig. 4-2E) levels. The MG scavenger, ALA, attenuated the increase in catecholamines, angiotensin, renin and aldosterone caused by MG (Fig. 4-2).

**MG increases alpha1D receptor, AT1 receptor and angiotensin expression in vascular smooth muscle cells and the aorta.**

Glucose is a major precursor of MG formation (Dhar et al., 2008). Incubation of VSMCs with MG (30 µM) or high glucose (25 mM) for 24 h (Fig. 4-3Ai, ii, B) or 5 days (supplemental Fig. 4-S1) caused a significant increase in adrenergic α1D receptor, angiotensin AT1 receptor and angiotensin protein and mRNA, which were attenuated by ALA (Figs. 4-3Ai, ii, B, supplemental Fig. 4-S1).

Chronic treatment of SD rats with MG for 4 weeks significantly elevated aortic adrenergic α1D receptor, angiotensin AT1 receptor and angiotensin protein and mRNA, which were attenuated by co-treatment with ALA + MG (Fig. 4-3Aiii, C).

**Chronic treatment of Sprague-Dawley rats with methylglyoxal increases renal AT1 receptor, renin and angiotensin expression**

Chronic treatment of Sprague-Dawley rats with MG for 4 weeks significantly increased renal AT1 receptor, renin and angiotensin protein and mRNA, which were attenuated by co-treatment with ALA (Fig. 4-4A, B).
Acute or chronic treatment with MG increases phosphorylated extracellular signal related kinases 1/2 (p-Erk 1/2) and NFATc expression

Incubation of VSMCs with MG (30 µM) for 24 h (Fig. 4-5A) caused an increase in phosphorylated Erk 1/2 (p-Erk 1/2) and NFATc protein expression which was attenuated by ALA (Fig. 4-5A). Chronic treatment of Sprague-Dawley rats with MG for 4 weeks increased aortic and renal protein expression of p-Erk 1/2 and NFATc, which was attenuated by ALA (Figs. 4-5B, C).

Effects of inhibition of NF-κB or angiotensinogen siRNA and receptor for AGEs (RAGE) siRNA on MG induced increase in NF-κB, angiotensin, AT₁ and α₁D receptors in VSMCs

Incubation of VSMCs with MG (30 µM) for 24 h caused a significant increase in the protein and mRNA for NF-κB, angiotensin, AT₁ and adrenergic α₁D receptors, which were attenuated by co-incubation with the NF-κB inhibitor CAY 10512 (0.1 µM) or the MG scavenger, ALA (100 µM) (Fig. 4-6A-D). RAGE siRNA attenuated the increase in RAGE and NF-κB p65 protein expression induced by MG (30 µM) in cultured VSMCs (Fig. 4-6E). Angiotensinogen siRNA attenuated the increase in NF-κB p65, angiotensin, AT₁ and adrenergic α₁D receptor protein expression induced by MG (30 µM) in cultured VSMCs (Fig. 4-6F).

4.5 Discussion

We report the novel finding that MG, a reactive metabolite produced from glucose and fructose, significantly increases renin angiotensin aldosterone levels associated with an increase in the BP in Sprague-Dawley rats. Molecular studies in cultured VSMCs implicate RAGE and
NF-κB in the signaling pathway of MG to cause these effects. Alagebrium attenuates the pathological effects of MG on the RAAS.

The association of hypertension, and increased cardiovascular fatalities such as myocardial infarction and stroke, with diabetes is well established (Ferrannini et al., 2012; Gee et al., 2012). High glucose (Kaufman et al., 1991) and high fructose diets (Hwang et al., 1987; Madero et al., 2011) have been shown to significantly increase the BP in animals and humans but the molecular mechanisms are not very clear. In the case of high glucose diet activation of protein kinase C, increased oxidative stress and reduced bioavailability of NO have been reported (Brownlee, 2001). In the case of high fructose diet one proposed mechanism implicates unregulated metabolism of fructose causing ATP depletion and an increase in uric acid, oxidative stress and decrease in NO production (Perez-Pozo et al., 2010; Sanchez-Lozada et al., 2007). Glucose and fructose are both precursors of MG formation (Dhar et al., 2008) and MG in turn is a well-established trigger for increased oxidative stress through multiple pathways (Desai et al., 2008). MG is also a major precursor of the formation of AGEs (Ahmed et al., 1997; Vander Jagt et al., 2003).

To the best of our knowledge our study is the first one to report a direct effect of MG on the development of hypertension and the probable molecular mechanisms. One study had reported administration of MG in drinking water for 18 weeks, and an increase in BP (Vasdev et al., 1998; Vasdev et al., 2010) but a direct link between MG and increased BP was not established. For example, plasma or aortic or renal MG levels were not measured. Instead renal levels of aldehyde conjugates (AGEs) were measured which likely represent modification of several proteins/enzymes, and do not identify individual proteins/enzymes and molecular
mechanisms. Moreover, in their study (Vasdev et al., 1998; Vasdev et al., 2010) the authors did not address the role of the RAAS. Moreover, MG reacts with epithelial cells of the intestines and the colon (Baskaran et al., 1990) and its oral bioavailability is questionable. An association of elevated MG with hypertension in rats has been shown but the cause effect relation was not established (Wang et al., 2007b; Wang et al., 2008).

Increased activity of the RAAS is seen in type 2 diabetics with hypertension (Hsueh et al., 2011). Hyperglycemia and diabetes are known to increase renin angiotensin activity but the mechanism has not been clearly defined. In one study high levels of glucose were shown to cause the release of renin through local accumulation of succinate and activation of the kidney-specific G protein-coupled receptor, GPR91, in the glomerular endothelium in rat, mouse, and rabbit (Toma et al., 2008). In another study 25 mM D-glucose increased the expression of angiotensinogen gene in cultured immortalized rat proximal tubular cells through synthesis of diacylglycerol and activation of protein kinase C (Toma et al., 2008; Zhang et al., 1999). We decided to examine the effect of MG on the RAAS.

The oral absorption of MG is doubtful as determined in our preliminary studies, which failed to cause any significant increase in plasma MG levels. Therefore, we administered MG by continuous infusion of very small amounts with a minipump (Dhar et al., 2011), hoping to simulate the almost continuous production of MG in the body through metabolism. Administration of the dose of MG used in this study by minipump results in significant elevation of plasma MG levels to values reported in pathological conditions (Wang et al., 2005; Wang et al., 2008) and in our previous study (Dhar et al., 2011). This mode of MG administration significantly elevated MG levels in the kidney and the aorta (Fig. 4-1), which implicates MG in
the pathological effects on the RAAS. MG treatment increased plasma levels of renin, angiotensin, aldosterone and catecholamines (Fig. 4-2) signifying increased RAAS and adrenergic activity, which most likely increased the blood pressure. The kidney is the main source of renin and the major regulator of BP. The kidney had increased protein expression of renin, which would explain increased plasma renin. The renin in turn would produce more angiotensin II and its multiple effects (Fyhrquist et al., 2008; Hitomi et al., 2007; Zaman et al., 2002).

The aorta had significantly elevated MG. Previously we have shown that the aorta has significantly elevated levels of MG compared to other organs and tissues in normal SD rats, the reason being unknown, and it increases further after an acute infusion of MG (Dhar et al., 2010a). The increased MG most likely increased aortic AT₁ receptor, α₁D receptor and angiotensin, because these effects were attenuated by the MG scavenger ALA. Both AT₁ and α₁D receptor activation can increase p-Erk 1/2 and NFATc, as seen here, which can contribute to increased vascular tone, inflammation and hypertension development (Hitomi et al., 2007). Increased AT₁ and α₁D receptors can increase vascular tone and BP (Fyhrquist et al., 2008; Zaman et al., 2002). We have previously shown (Dhar et al., 2010b) that MG can reduce endothelial nitric oxide synthase activity which can contribute to increased BP, although it was not investigated in this study.

Treatment of VSMCs with MG or high glucose caused a similar significant increase in cellular MG levels, along with increased expression of AT₁ receptor, α₁D receptor and angiotensin, which were all attenuated by ALA (Fig. 4-1), which is a MG scavenger and an AGEs breaker (Dhar et al., 2010a; Wolffinbuttel et al., 1998). Since the attenuation by ALA of
increased MG levels, AT₁ receptor, α₁D receptor and angiotensin occurred within 24 h in cultured VSMCs (Fig. 4-3), this indicates a direct effect of MG on AT₁ receptor, α₁D receptor and angiotensin, rather than an indirect effect through MG-induced AGEs, which normally take 5-7 days to form. High glucose similarly increased AT₁ receptor, α₁D receptor and angiotensin expression in VSMCs, which was attenuated by a MG scavenger, implicating MG as a mediator of the deleterious effects of hyperglycemia (Fig. 4-3). Since MG is a major precursor of AGEs formation, part of alagebrium’s preventive effects against MG could be due to prevention of AGEs formation in vivo, but not in 24 h cell culture studies.

We investigated whether the effect of MG on angiotensin, AT₁ and α₁D receptors was direct, or indirect through some other mediators. RAGE is currently under intense investigation as a target to prevent diabetic complications (Ramasamy et al., 2011). The activation of RAGE by AGEs has been reported to increase two key transcription factors, NF-κB and early growth response-1 (Egr-1), and cause oxidative stress (Ramasamy et al., 2011; Wendt et al., 2002). We report the novel finding that MG can activate RAGE and up regulate it (Fig. 4-6E). RAGE is a receptor which is up regulated by its other known ligands (Ramasamy et al., 2011). Thus, when we silenced RAGE we were able to prevent the increase in NF-κB induced by MG (Fig. 4-6E). When we inhibited NF-κB we were able to prevent the increase in angiotensin, AT₁ and α₁D receptors in VSMCs (Fig. 4-6B-D), indicating an indirect effect of MG on these parameters. When we silenced angiotensin mRNA we were able to prevent the increase in angiotensin, AT₁ and α₁D receptors and also the increase in NF-κB induced by MG (Fig. 4-6F). These results indicate that MG activates RAGE which then increases NF-κB followed by angiotensin, AT₁ and α₁D receptors. The increased angiotensin II in turn increases NF-κB and sets up a vicious cycle.
Our results establish a probable sequence of molecular events resulting from elevated MG levels which have been reported in high carbohydrate diet fed animals and in diabetic patients (Wang et al., 2007a; Wang et al., 2008).

4.6 Conclusions

We have shown a direct effect of MG in the development of hypertension and identified the probable involvement of the RAAS and RAGE in molecular mechanisms. Since diabetic patients are known to have significantly elevated MG levels (Wang et al., 2007a) and many people with diabetes develop hypertension, MG could possibly be a mediator of hyperglycemia-induced and diabetes associated hypertension. High carbohydrate diets are known to induce hypertension in animal models and since glucose and fructose are both precursors for MG formation, MG could very likely be causing high dietary carbohydrate-induced hypertension, which is currently being investigated by us. The involvement of MG as one of the causative factors of hypertension and activator of RAGE opens up the possibility of using effective and safe MG scavengers in preventing diabetes associated hypertension and vascular complications. While the dietary habits of millions of people worldwide and the use of high fructose containing processed foods is not likely to change overnight, preventive strategies will play a major role in attenuating the adverse health effects of high carbohydrate diets.

Acknowledgements

This work was supported by a grant-in-aid from the Heart and Stroke Foundation of Saskatchewan to KD and LW, and by a New Investigator grant from the Saskatchewan Health Research Foundation to KD.
Figure 4-1. Methylglyoxal levels in cultured vascular smooth muscle cells and in the aorta and kidney of chronic methylglyoxal treated Sprague-Dawley rats. Vascular smooth muscle cells (A10 cell line) were incubated with MG (30 µM) or high glucose (Glu, 25 mM) for 24 h (A) or 5 days (B). Alagebrium (30 µM) was used as a MG scavenger. Groups (n = 7 each) of 12 week old male Sprague-Dawley rats were treated for 4 weeks with a continuous infusion of methylglyoxal (MG, 24 mg/day) delivered by a subcutaneous minipump (C, D). Control rats received 0.9% saline by pump. Alagebrium (ALA, 100 mg/kg/day in drinking water) was used as a MG scavenger. MG levels were determined with HPLC. *P<0.05, **P<0.01 vs. respective control (Con). †P<0.05, ††P<0.01 vs. respective MG. ‡P<0.05, ‡‡P<0.01 vs. respective Glu group.
Figure 4-2. Mean arterial blood pressure, plasma catecholamines, angiotensin, renin, and aldosterone levels in chronic methylglyoxal treated Sprague-Dawley rats. Groups (n = 7 each) of 12 week old male Sprague-Dawley rats were treated for 4 weeks with a continuous infusion of methylglyoxal (MG, 24 mg/day) delivered by a subcutaneous minipump. Control rats received 0.9% saline by pump. Alagebrium (ALA, 100 mg/kg/day in drinking water) was used as a MG scavenger. Blood was collected and plasma was separated for analysis of MG by HPLC and catecholamines, renin, angiotensin and aldosterone by assay kits. *P<0.05, **P<0.01, ***P<0.001 vs. respective control. †P<0.05, ††P<0.01, †††P<0.001 vs. respective MG group.
Figure 4-3. $\alpha_1D$ receptor, AT$_1$ receptor and angiotensin protein expression in cultured vascular smooth muscle cells and in the aorta and mRNA in VSMCs and aorta of chronic methylglyoxal treated Sprague-Dawley rats. Rat thoracic aorta smooth muscle cells (VSMCs, A10 cell line) were cultured and incubated with MG (30 µM) (Ai, B) or high glucose (Glu, 25 mM) (Aii, B) for 24 h. Alagebrium (ALA, 30 µM) was used as a MG scavenger. Groups ($n = 7$ each) of 12 week old male Sprague-Dawley rats were treated for 4 weeks with a continuous infusion of methylglyoxal (MG, 24 mg/day) delivered by a subcutaneous minipump (Aiili, C). Control rats received 0.9% saline by pump. ALA (100 mg/kg/day in drinking water) was used as a MG scavenger. Protein expression was determined by Western blotting using appropriate
primary antibodies, and mRNA with RT-PCR. *$P<0.05$, **$P<0.01$ vs. respective control (Con).

$\dagger P<0.05$, $\ddagger P<0.01$ vs. respective MG group. $\ddagger P<0.05$ vs. respective Glu group.
Figure 4-4. AT₁ receptor, renin and angiotensin protein expression and mRNA in the kidney of chronic methylglyoxal treated Sprague-Dawley rats. Groups (n = 7 each) of 12 week old male Sprague-Dawley rats were treated for 4 weeks with a continuous infusion of methylglyoxal (MG, 24 mg/day) delivered by a subcutaneous minipump. Control rats received 0.9% saline by pump. Alagebrium (ALA, 100 mg/kg/day in drinking water) was used as a MG scavenger. Protein expression was determined by Western blotting using appropriate primary antibodies, and mRNA with RT-PCR. *P<0.05, **P<0.01 vs. respective control (Con). †P<0.05, ‡P<0.01 vs. respective MG group.
Figure 4-5. Phosphorylated extracellular signal-related kinases 1/2 (p-Erk 1/2), Erk 1/2 and NFATc expression in cultured vascular smooth muscle cells, and in the aorta and kidney of chronic methylglyoxal treated Sprague-Dawley rats. Rat thoracic aorta smooth muscle cells (VSMCs, A10 cell line) were cultured and incubated with MG (30 µM) (A) for 24 h. Alagebrium (ALA, 30 µM) was used as a MG scavenger. Groups (n = 7 each) of 12 week old male Sprague-Dawley rats were treated for 4 weeks with a continuous infusion of methylglyoxal (MG, 24 mg/day) delivered by a subcutaneous minipump (B, C). Control rats received 0.9% saline by pump. ALA (100 mg/kg/day in drinking water) was used as a MG scavenger. Protein expression was determined by Western blotting using appropriate primary antibodies, and mRNA with RT-PCR.
Figure 4-6. Nuclear factor κB (NF-κB), angiotensin, AT₁ receptor, α₁D receptor and receptor for advanced glycation endproducts (RAGE) expression in cultured vascular
smooth muscle cells treated with a NF-κB inhibitor, or after RAGE siRNA or angiotensinogen siRNA treatment. Vascular smooth muscle cells (A10 cell line) were cultured and incubated with MG (30 µM) for 24 h. CAY 10512 (0.1 µM) was used a NF-κB inhibitor. Alagebrium (ALA, 30 µM) was used as a MG scavenger (A-D). RAGE siRNA (E) or angiotensinogen siRNA (F) was carried out as explained in methods. Protein expression was determined by Western blotting using appropriate primary antibodies, and mRNA with RT-PCR. n = 4 for each group. ***P<0.001 vs. respective control. †††P<0.001 vs. respective MG group.
Figure 4-S1. α1D receptor, AT1 receptor and angiotensin expression in cultured vascular smooth muscle cells treated with methylglyoxal or high glucose. Rat thoracic aorta smooth muscle cells (A10 cell line) were cultured and incubated with MG (30 µM) (A, C) or high glucose (Glu, 25 mM) (B, D) for 5 days. Alagebrium (ALA, 30 µM) was used as a MG scavenger. Protein expression was determined by Western blotting using appropriate primary antibodies, and mRNA with RT-PCR. *P<0.05, **P<0.01 vs. respective control (Con).
CHAPTER 5

Increased methylglyoxal formation with upregulation of renin angiotensin system in fructose fed Sprague Dawley rats.

Indu Dhar¹, Arti Dhar¹, Lingyun Wu²*, Kaushik M Desai¹*

¹Department of Pharmacology, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 5E5 SK, Canada

²Department of Health Sciences, Lakehead University, Thunder Bay, ON, Canada

& Thunder Bay Regional Research Institute, Thunder Bay, ON, Canada

This chapter has been published as a paper in

*PLoS One, 2013; 8(9):e74212*

Contents of this chapter have been adapted / reproduced from the published article with permission from the journal “PLoS One”
5.1 Abstract

The current epidemic of obesity and type 2 diabetes is attributed to a high carbohydrate diet, containing mainly high fructose corn syrup and sucrose. More than two thirds of diabetic patients have hypertension. Methylglyoxal is a highly reactive dicarbonyl generated during glucose and fructose metabolism, and a major precursor of advanced glycation end products (AGEs). Plasma methylglyoxal levels are increased in hypertensive rats and diabetic patients. Our aim was to examine the levels of methylglyoxal, mediators of the renin angiotensin system and blood pressure in male Sprague-Dawley rats treated with a high fructose diet (60% of total calories) for 4 months. The thoracic aorta and kidney were used for molecular studies, along with cultured vascular smooth muscle cells (VSMCs). HPLC, Western blotting and Q-PCR were used to measure methylglyoxal and reduced glutathione (GSH), proteins and mRNA, respectively. Fructose treated rats developed a significant increase in blood pressure. Methylglyoxal level and protein and mRNA for angiotensin II, AT1 receptor, adrenergic α1D receptor and renin were significantly increased, whereas GSH levels were decreased, in the aorta and/or kidney of fructose fed rats. The protein expression of the receptor for AGEs (RAGE) and NF-κB were also significantly increased in the aorta of fructose fed rats. MG treated VSMCs showed increased protein for angiotensin II, AT1 receptor, and α1D receptor. The effects of methylglyoxal were attenuated by metformin, a methylglyoxal scavenger and AGES inhibitor. In conclusion, we report a strong association between elevated levels of methylglyoxal, RAGE, NF-κB, mediators of the renin angiotensin system and blood pressure in high fructose diet fed rats.

Key words: Methylglyoxal, hypertension, renin angiotensin system, diabetes, fructose, receptor for advanced glycation endproducts.
5.2 Introduction

High dietary carbohydrates, increasing type 2 diabetes and obesity, and the associated hypertension and cardiovascular diseases are major health issues globally (Johnson et al., 2007; Selvaraju et al., 2012; Stanhope, 2012). The explosive increase in type 2 diabetes in the past 2-3 decades has been attributed to high dietary carbohydrates, especially fructose, combined with a sedentary lifestyle. Compared to the general population the risk of high blood pressure (BP, systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg) is four times higher for people with diabetes (Diabetes, 2000). The pathogenesis of diabetes-associated hypertension is not clearly known. While it is believed to be initiated by hyperglycemia, the molecular mechanisms are far from clear.

The Western diet has high fructose content, mainly in the form of high fructose corn syrup, which has been proposed to induce hypertension (Johnson et al., 2007; Stanhope, 2012). High fructose diet-fed Sprague-Dawley rats have been widely used as a model of insulin resistance and these rats also develop hypertension (Hwang et al., 1987; Wang et al., 2008).

We have shown that fructose-fed Sprague-Dawley rats have elevated levels of methylglyoxal (MG), a reactive metabolite of glucose and fructose (Wang et al., 2008; Dhar et al., 2008). Elevated plasma levels of MG have been reported in spontaneously hypertensive rats which correlate with the degree of hypertension (Wang et al., 2005; Wang et al., 2007), but the cause-effect relationship and the underlying molecular mechanisms are not known. People with diabetes have significantly elevated levels of MG (Wang et al., 2007; McLellan et al., 1994). We have recently reported that chronic MG induces features of type 2 diabetes in SD rats (Dhar et al., 2011). MG is a major precursor for the formation of advanced glycation end products.
(AGEs) (Desai & Wu, 2007; Vander & Husankar, 2003). MG reduces activity of antioxidant enzymes like glutathione reductase and glutathione peroxidase (Wu & Juurlink, 2002); leading to increased oxidative stress, which in turn is believed to cause the pathophysiological changes in diabetes, hypertension, and aging (Ceriello & Motz, 2004; Harman D, 1998). The pathogenesis of hypertension is multifactorial. Some of the factors include an increase in renin angiotensin aldosterone system (RAAS) activity, insulin resistance, renal disease and oxidative stress (Ceriello A, 2008; Cowley & Roman, 1996; Hall et al., 1990; Manrique et al., 2009). The RAAS plays an important role in maintaining fluid balance, vascular tone and blood pressure (Fyhrquist & Saijonmaa 2008; Zaman et al., 2002). MG and angiotensin II (Ang II) both lead to an increase in oxidative stress (Manrique et al., 2009; Hitomi et al., 2007; Desai & Wu, 2008). Ang II stimulates NADPH oxidase by acting through the AT$_1$ receptor and increases superoxide, hydrogen peroxide, and peroxynitrite (Hitomi et al., 2007). However, the cause and effect relationship between increased oxidative stress, RAAS activity and increased blood pressure has remained unclear.

Therefore, the aim of this study was to examine and correlate the levels of MG, mediators of the renin angiotensin system and blood pressure in high fructose diet fed Sprague-Dawley rats.

### 5.3 Materials and methods

**Animals**

Male Sprague-Dawley rats from Charles River Laboratories (Quebec, Canada) were used according to guidelines of the Canadian Council on Animal Care. All animal protocols were
approved by the University of Saskatchewan’s Animal Research Ethics Board. 32 male 5 week old Sprague-Dawley rats were randomly divided into the following treatment groups (n = 8 in each group): 1. Control (normal rat chow), 2. High fructose diet (60% of total calories), 3. High fructose diet + metformin (500 mg/kg/day in drinking water, MG scavenger (Beisswenger et al., 1999; Ruggiero-Lopez et al., 1999), 4. Metformin (normal chow). The treatments were for 16 weeks.

At the end of the treatment period, the rats were anaesthetized with sodium pentobarbital (60 mg/kg body weight, i.p.). The trachea was cannulated to allow spontaneous respiration. The carotid artery was cannulated and connected to a pressure transducer and a Powerlab system (AD Instruments Inc., Colorado Springs, CO, USA) using LabChart 7 software. After 15 min stabilization the blood pressure was recorded for 30 min (Desai et al., 2006). Blood was collected from the carotid artery and plasma was separated and stored at -80°C. The anesthetized rat was euthanized by cutting the thorax and the heart, and causing exsanguination, as per the guidelines of the Canadian Council on Animal Care. Organs and tissues cleaned in ice-cold phosphate buffer saline were immediately frozen in liquid nitrogen and stored at -80°C until processing.

Cell culture

Rat thoracic aortic smooth muscle cells (A-10 cells, CRL-1476, American Type Culture Collection, Manassas, VA, USA) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal bovine serum (FBS), 1% penicillin-streptomycin at 37°C in a humidified atmosphere of 95% air and 5% CO₂, as described in our previous study (Dhar et al.,...
The cells were seeded in 100 mm dishes, with an equal amount of cells (10^6/mL) in each dish, and cultured to confluence. Cells were starved in FBS-free DMEM medium for 24 h prior to exposure to different treatments alone or in combination: MG (30 µM based on preliminary results), and metformin (100 µM).

**Methylglyoxal measurement**

MG was measured by a specific and sensitive high-performance liquid chromatography (HPLC) method as described earlier (Dhar et al., 2009). MG was derivatized with o-phenylenediamine to form the quinoxaline product, 2-methylquinoxaline, which is very specific for MG. The 2-methylquinoxaline and the internal standard 5-methylquinoxaline were quantified on a Hitachi D-7000 HPLC system (Hitachi, Ltd., Mississauga, ON, Canada) via a Symmetry C18 column (3.9 x 150 mm, and 4 µm particle diameter; Waters Corp., Milford, MA, USA).

**Western blotting**

Total proteins from cultured cells, aorta and kidney, were isolated with RIPA (lysis) buffer using a polytron homogenizer. The supernatants (40 µg of protein each) were separated by using 6-10% SDS-PAGE gel and subjected to Western blot analysis as previously described (Dhar et al., 2011) with overnight incubation with primary antibodies to AT₁ receptor for angiotensin (AT₁R), adrenergic α₁D receptor (α₁D-R), renin, Ang II, (all from Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), receptor for AGEs (RAGE), nuclear factor κB (NF-κB) (Abcam, Cambridge, MA, USA), and anti-β-actin (diluted 1:1000) (Sigma-Aldrich Canada Ltd., Mississauga, ON, Canada). This was followed by incubation with horse radish peroxidase.
conjugated secondary antibodies (Life Science, Hercules, CA, USA) (diluted 1:3000) for 2 h at room temperature. The proteins were then visualized with ECL chemiluminescence reagent (GE Healthcare Life Sciences, Pittsburgh, PA, USA) and exposed to X-ray film (GE Healthcare Life Sciences, Pittsburgh, PA, USA).

**Real time quantitative PCR (RT-PCR)**

Total RNA from the kidney and the aorta was isolated using RNA isolation kit (Qiagen, Germantown, MD, USA). The pre-designed primers for Ang II, AT1R, α1D, renin and RAGE were purchased from Qiagen, (Germantown, MD, USA). The real-time PCR was performed in an iCycler iQ apparatus (Life Science, Hercules, CA, USA) associated with the ICYCLER OPTICAL SYSTEM software (version 3.1) using SYBR Green PCR Master Mix (Bio-Rad Laboratories Ltd., Mississauga, ON, Canada).

**Measurement of reduced glutathione (GSH)**

Reduced glutathione was measured by derivatization with 5,5’-dithio-bis(2-nitrobenzoic acid), and reverse-phase HPLC using ultraviolet detection (Wang et al., 2008).

**Statistical Analysis**

Data obtained from separate experiments are expressed as mean ± SEM. Statistical analysis was performed using ANOVA with post hoc Bonferroni’s test. A $P$ value of less than 0.05 was considered to be statistically significant.
5.4 Results

**Chronic fructose treatment increases blood pressure, aortic and renal methylglyoxal levels**

Treatment of Sprague-Dawley rats with a high fructose diet for 16 weeks caused a significant increase in the blood pressure, which was attenuated by the MG scavenger metformin (Fig. 5-1A). Metformin alone did not affect the blood pressure. The high fructose diet also caused a significant elevation of aortic and renal MG levels, which was attenuated by co-treatment with metformin (Fig. 5-1B, C).

**Chronic treatment with fructose increases aortic α₁D receptor, AT₁ receptor and angiotensin II expression**

Chronic treatment of Sprague-Dawley rats with fructose for 16 weeks significantly elevated aortic adrenergic α₁D receptor, angiotensin AT₁ receptor and Ang II protein and mRNA, which were attenuated by co-treatment with metformin (Fig. 5-2). Metformin alone was without any effect.

**Chronic treatment of Sprague-Dawley rats with fructose increases renal AT₁ receptor, renin and angiotensin II expression**

Chronic treatment of Sprague-Dawley rats with fructose for 16 weeks significantly increased renal AT₁ receptor, renin and Ang II protein and mRNA, which were attenuated by co-treatment with metformin (Fig. 5-3). Metformin alone was without any effect.

**Chronic treatment with fructose increases phosphorylated extracellular signal related**
kinases 1/2 (p-Erk 1/2), and NFATc expression

Chronic treatment of Sprague-Dawley rats with fructose for 16 weeks increased aortic and renal protein expression of phosphorylated Erk 1/2 (p-Erk 1/2) and NFATc in the aorta, which was attenuated by metformin (Fig. 5-4A, B).

**Chronic treatment with fructose increases NF-κB and RAGE protein expression**

Chronic treatment of SD rats with fructose for 16 weeks significantly increased aortic and renal NF-κB and RAGE protein expression, which was attenuated by co-treatment with metformin (Fig. 5-5A, B).

**Chronic treatment with fructose decreases levels of reduced glutathione in the aorta and kidney**

Chronic treatment of Sprague-Dawley rats with fructose for 16 weeks significantly decreased aortic and renal levels of reduced glutathione, which were attenuated by co-treatment with metformin (Fig. 5-6A, B).

**Methylglyoxal increases α₁D receptor, AT₁ receptor and angiotensin II expression in cultured vascular smooth muscle cells**

Treatment of rat thoracic aortic cultured vascular smooth muscle cells with MG (30 µM) for 24 h significantly elevated adrenergic α₁D receptor, angiotensin AT₁ receptor and Ang II protein, which were attenuated by co-treatment with metformin (Fig. 5-7). Metformin alone was without any effect.
Metformin has MG scavenging ability

As shown in table 1, 100 µM metformin significantly reduced the detectable free MG in solution after 3 h incubation, and about 30% of MG was detectable after 24 h incubation. A higher concentration of metformin (1 mM) was more effective in scavenging MG and it significantly reduced detectable free MG after 1 h of incubation and only about 10% of MG was detectable after 24 h.

5.5 Discussion

Here we show that 12 week old male Sprague-Dawley rats treated for 16 weeks with a high fructose diet, a precursor of MG, develop a significant increase in blood pressure. The kidney and aorta from fructose treated rats had significantly increased MG levels, and protein and mRNA for renin, Ang II, AT₁ and adrenergic α₁D receptors, which were attenuated by the MG scavenger metformin. MG treated cultured vascular smooth muscle cells had increased expression of Ang II, AT₁ and α₁D receptors, which was attenuated by metformin.

Although high glucose (Kaufman et al., 1991) and high fructose diets (Hwang et al., 1987; Madero et al., 2011) have been shown to significantly increase the blood pressure in animals and humans, the molecular mechanisms are not very clear. A high glucose diet-induced increase in blood pressure has been attributed to activation of protein kinase C, increased oxidative stress and reduced bioavailability of nitric oxide (Brownlee M, 2001). Fructose is metabolized differently than glucose with up to 75% of orally absorbed fructose being metabolized by the liver (Johnson et al., 2009). Moreover, the key enzyme of fructose metabolism, fructokinase is not feedback regulated by fructose metabolites (Johnson et al., 2009).
Thus, all of the orally absorbed fructose is phosphorylated by fructokinase (Johnson et al., 2009; Le et al., 2012). Unregulated metabolism of fructose causing ATP depletion, oxidative stress and decrease in nitric oxide production has been proposed as one of the mechanisms of fructose-induced increase in blood pressure (Perez-Pozo et al., 2010; Sanchez-Lozada et al., 2007). Both glucose and fructose are precursors of MG formation (Dhar et al., 2008) and MG is also a well-established trigger for increased oxidative stress through multiple pathways (Desai & Wu, 2008). MG is also a major precursor of the formation of AGEs. (Desai & Wu, 2007; Vander & Husankar, 2003).

The aorta and the kidney of fructose treated rats had significantly elevated MG levels (Fig. 5-1) which implicates MG as a factor in hypertension development. The kidney had increased protein expression of renin, which in turn would produce more Ang II and its multiple effects (Hitomi et al., 2007). The increased aortic MG, as observed in the present study, most likely increased aortic AT₁ receptor, α₁D receptor and Ang II. This effect of MG was confirmed by increased expression of AT₁ receptor, α₁D receptor and Ang II in MG treated cultured vascular smooth muscle cells (Fig. 5-7). Both AT₁ and α₁D receptor activation can increase p-Erk 1/2, and NFATc, as seen here, which can contribute to increased vascular contractility, inflammation and hypertension development (Hitomi et al., 2007; Michelotti et al., 2000). The increased Ang II may be responsible for the increased α₁D receptor expression (Fyhrquist & Saijonmaa, 2008; Zaman et al., 2000). The increased Ang II, AT₁ and α₁D receptors in the aorta signify increased vascular tone. We were not able to harvest enough tissue from the mesenteric artery for western blot and PCR analysis. GSH levels were reduced in the aorta and the kidney of fructose treated rats (Fig. 5-6). GSH plays a central role in the degradation of MG by binding MG and making it
available to the glyoxalase enzymes (Vander & Husankar, 2003). A reduction in GSH would decrease MG degradation, increase its levels, and set up a vicious cycle.

We addressed the possibility that MG was increasing oxidative stress, which has been implicated in the pathogenesis of hypertension (Ceriello A, 2008). The effect of MG on RAGE has not been reported before. RAGE is currently under intense investigation as a target to prevent diabetic complications. The activation of RAGE by AGEs has been reported to increase two key transcription factors, NF-κB and early growth response-1 (Egr-1), and cause oxidative stress (Ramasamy et al., 2011; Wendt et al., 2002). We observed increased RAGE and NF-κB in the aorta and the kidney of fructose treated rats. These results suggest that fructose treatment increases MG levels, which in turn can activate RAGE, which then increases NF-κB and oxidative stress. The increased oxidative stress increases expression of Ang II, AT₁ and α₁D receptors. The increased Ang II in turn can increase NF-κB and oxidative stress (Hitomi et al., 2007) and set up a vicious cycle. Our results suggest a possible sequence of molecular events resulting from elevated endogenous MG levels which have been reported in high carbohydrate diet fed animals and in diabetic patients (Hwang et al., 1987; Wang et al., 2008; Wang et al., 2007; McLellan et al., 1994).

Metformin is used clinically as an oral anti-diabetic drug in patients with type 2 diabetes. Metformin has multiple effects in vivo. For example, it inhibits mitochondrial respiration and gluconeogenesis in the liver, activates AMP-activated protein kinase, increases insulin sensitivity, antagonizes the action of glucagon and increases fatty acid oxidation (Rena et al., 2013). These in vivo antidiabetic actions of metformin can make interpretation of results difficult, making it a less than ideal experimental MG scavenger. Even though the MG
scavenging ability of metformin has been studied in specific experiments and reported before (Beisswenger et al., 1999; Ruggiero-Lopez et al., 1999), we tested the MG scavenging ability of metformin in cultured vascular smooth muscle cells treated with MG, where multiple *in vivo*, especially hepatic, actions of metformin do not come into play. We also performed an *in vitro* MG scavenging assay for metformin. In cultured vascular smooth muscle cells metformin attenuated the increased expression of α₁D and AT₁ receptors, and Ang II (Fig. 5-7). These results support a direct effect of MG on these RAAS mediators and the MG scavenging action of metformin. As shown in table 1 metformin displayed significant MG scavenging ability when the two were mixed in solution.

### 5.6 Conclusions

In conclusion, high fructose diet fed rats had significantly elevated blood pressure, MG levels in the aorta, and the kidney, and increased expression of Ang II, AT₁ receptor, α₁D receptor, renin, RAGE and NF-κB and decreased levels of reduced glutathione in the aorta and/or the kidney. The MG scavenger metformin attenuated these effects. Our results show a strong association between elevated levels of methylglyoxal, RAGE, NF-κB, mediators of the renin angiotensin system and blood pressure in high fructose diet fed rats. Therefore, it is possible that MG could be a mediator of high fructose diet-induced hypertension, probably acting through RAGE and NF-κB, and up regulating the renin angiotensin system.
Figure 5-1. Mean arterial blood pressure and methylglyoxal (MG) levels in the aorta and kidney of high fructose diet treated Sprague-Dawley rats. Groups (n = 8 each) of 5 week old male Sprague-Dawley rats were treated for 16 weeks with a high fructose diet (Fruc, 60% of total calories). Control rats received normal chow. Metformin (Met, 500 mg/kg/day in drinking water) was used as a MG scavenger. Mean arterial pressure was measured with an intra-carotid artery catheter in anesthetized rats. MG levels were determined with HPLC. **P<0.01 vs. respective control (Con). †P<0.05, ††P<0.01 vs. respective Fruc group.
Figure 5-2. Adrenergic $\alpha_{1D}$ receptor ($\alpha_{1D}R$), AT$_1$ angiotensin receptor (AT$_1$R) and angiotensin II (Ang II) expression and mRNA in the aorta of high fructose diet treated Sprague-Dawley rats. Groups ($n = 8$ each) of 5 week old male Sprague-Dawley rats were treated for 16 weeks with a high fructose diet (Fruc, 60% of total calories). Control rats received normal chow. Metformin (Met, 500 mg/kg/day in drinking water) was used as a MG scavenger. Protein expression was determined by Western blotting using appropriate primary antibodies, and mRNA with RT-PCR. *$P<0.05$, **$P<0.01$ vs. respective control (Con). †$P<0.05$ vs. respective Fruc group.
Figure 5-3. AT₁ angiotensin receptor (AT₁R), renin and angiotensin II (Ang II) expression and mRNA in the kidney of high fructose diet treated Sprague-Dawley rats. Groups (n = 8 each) of 5 week old male Sprague-Dawley rats were treated for 16 weeks with a high fructose diet (Fruc, 60% of total calories). Control rats received normal chow. Metformin (Met, 500 mg/kg/day in drinking water) was used as a MG scavenger. Protein expression was determined by Western blotting using appropriate primary antibodies, and mRNA with RT-PCR. *P<0.05 vs. respective control (Con). †P<0.05 vs. respective Fruc group.
Figure 5-4. Phosphorylated extracellular signal-related kinases 1/2 (p-Erk 1/2), Erk 1/2 and NFATc expression in the aorta and kidney of high fructose diet treated Sprague-Dawley rats. Groups ($n = 8$ each) of 5 week old male Sprague-Dawley rats were treated for 16 weeks with a high fructose diet (Fruc, 60% of total calories). Control rats received normal chow. Metformin (Met, 500 mg/kg/day in drinking water) was used as a MG scavenger. Protein expression was determined by Western blotting using appropriate primary antibodies.
Figure 5-5. Receptor for advanced glycation endproducts (RAGE) and nuclear factor κB (NF-κB) expression in the aorta and kidney of high fructose diet treated Sprague-Dawley rats. Groups (n = 8 each) of 5 week old male Sprague-Dawley rats were treated for 16 weeks with a high fructose diet (Fruc, 60% of total calories). Control rats received normal chow. Metformin (Met, 500 mg/kg/day in drinking water) was used as a MG scavenger. Protein expression was determined by Western blotting using appropriate primary antibodies.
Figure 5-6. Reduced glutathione (GSH) levels in the aorta and kidney of high fructose diet treated Sprague-Dawley rats. Groups (n = 8 each) of 5 week old male Sprague-Dawley rats were treated for 16 weeks with a high fructose diet (Fruc, 60% of total calories). Control rats received normal chow. Metformin (Met, 500 mg/kg/day in drinking water) was used as a MG scavenger. Glutathione levels were determined with HPLC. *P<0.05, **P<0.01 vs. respective control. †P<0.05, vs. respective Fruc group.
Figure 5-7. $\alpha_{1D}$ receptor ($\alpha_{1D}R$), AT1 receptor (AT$_1$R) and Angiotensin II (Ang II) expression in cultured vascular smooth muscle cells (VSMCs) treated with methylglyoxal. Rat thoracic aorta smooth muscle cells (A10 cell line) were cultured and incubated with MG (30 $\mu$M) for 24 h. Metformin (100 $\mu$M) was used as a MG scavenger. Protein expression was determined by Western blotting using appropriate primary antibodies. $n = 4$ for each group. *$P<0.05$, **$P<0.01$ vs. respective control (Con). †$P<0.05$, ††$P<0.01$ vs. respective MG group.
### Table 5-1. *In vitro* assay to determine the methylglyoxal (MG) scavenging ability of metformin.

MG was incubated with metformin at different concentrations at 37°C for different times. The solution was analyzed for free MG by HPLC after the given incubation period. The values (µM) are expressed as mean ± SEM (n = 6 in each).

<table>
<thead>
<tr>
<th>Incubation time</th>
<th>MG (30 µM)</th>
<th>MG (30 µM) + metformin (100 µM)</th>
<th>MG (30 µM) + metformin (1 mM)</th>
<th>Metformin (100 µM)</th>
<th>Metformin (1 mM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15 min</td>
<td>24.89 ± 0.15</td>
<td>21.69 ± 0.17</td>
<td>18.79 ± 0.21</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>30 min</td>
<td>25.28 ± 0.21</td>
<td>19.29 ± 0.06</td>
<td>15.28 ± 0.32</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>60 min</td>
<td>26.82 ± 0.15</td>
<td>17.87 ± 0.31</td>
<td>10.38 ± 0.51*</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>3 h</td>
<td>25.77 ± 0.14</td>
<td>12.52 ± 0.08*</td>
<td>7.36 ± 0.27**</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>24 h</td>
<td>25.23 ± 0.31</td>
<td>9.43 ± 0.41**</td>
<td>3.39 ± 0.32***</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
CHAPTER 6

Arginine attenuates methylglyoxal- and high glucose-induced endothelial dysfunction by an eNOS-independent mechanism

Indu Dhar, Arti Dhar, Lingyun Wu*, Kaushik Desai*

Department of Pharmacology, College of Medicine, University of Saskatchewan, Saskatoon, Canada

Running title: Arginine, methylglyoxal and endothelial dysfunction

This chapter has been published as a paper in

The Journal of Pharmacology and Experimental Therapeutics, 2012;

342:196-204

Contents of this chapter have been adapted / reproduced from the published article with permission from the journal “JPET"
6.1 Abstract

**Aims.** Methylglyoxal (MG), a reactive metabolite of glucose, has high affinity for arginine and is a major precursor of advanced glycation endproducts. Specific and safe MG scavengers are not available. We investigated whether L-arginine and D-arginine can attenuate endothelial dysfunction and oxidative stress induced by MG and high glucose, and implications for arginase for which L-arginine is a substrate.

**Methods and results.** We used isolated aortic rings from 12 week old male Sprague-Dawley rats and cultured human umbilical vein endothelial cells (HUVECs) and vascular smooth muscle cells (VSMCs). L- and D-arginine both attenuated MG and high glucose induced reduced endothelium-dependent relaxation by acetylcholine, but only L-arginine attenuated inhibition of relaxation by the nitric oxide synthase inhibitor, Nω-nitro-L-arginine methyl ester. MG and high glucose increased protein expression of arginase, NADPH oxidase 4, nuclear factor kappa B, and reactive oxygen species production in HUVECs and VSMCs, which were attenuated by L- and D-arginine. However, L- and D-arginine did not attenuate the MG and high glucose-induced increased arginase activity in VSMCs. MG and high glucose-induced increased formation of the MG-specific advanced glycation endproduct, Nε-carboxyethyl lysine, in VSMCs was attenuated by L- and D-arginine.

**Conclusions.** MG and high glucose increase arginase protein and activity which may contribute to endothelial dysfunction. L-arginine and D-arginine attenuate the endothelial dysfunction and increased oxidative stress induced by MG and high glucose by an endothelial nitric oxide synthase independent mechanism, despite increased arginase activity. The potential of arginine as a safe MG scavenger needs to be followed up.
6.2 Introduction

L-arginine (L-Arg), but not D-arginine (D-Arg), is a substrate for nitric oxide synthase (NOS), which catalyzes the formation of nitric oxide (NO) and L-citrulline (Palmer et al., 1988). There are three isoforms of NOS, endothelial NOS (eNOS), inducible NOS (iNOS) and neuronal NOS (nNOS) (Moncada et al., 1991). eNOS is mainly found in the endothelial cells and mediates endothelium-dependent agonist induced vessel relaxation (Moncada et al., 1991). Reduced production or availability of NO is a common feature of endothelial dysfunction (De Vriese et al., 2000; Potenza et al., 2009), which is commonly defined as reduced endothelium-dependent vascular relaxation, and is a feature of diabetes, atherosclerosis, hypertension and several other conditions.

L-Arg, but not D-Arg, is also a substrate for arginase, which is an enzyme of the urea cycle that catalyzes the formation of urea and ornithine. There are two isoforms, arginase I and arginase II (Haraguchi et al., 1987; Morris et al., 1997). In blood vessels, arginases are mainly expressed in the endothelium and at low levels in vascular smooth muscle cells (VSMCs) (Wei et al., 2000). Increased expression of VSMC arginase may contribute to intimal hyperplasia and vascular stiffness (Marinova et al., 2008; Wei et al., 2001). Endothelial arginase may be affecting eNOS function and can be responsible for endothelial dysfunction (Berkowitz et al., 2003; Zhang et al., 2001). High glucose (25 mM) has been shown to increase arginase I activity, but not protein expression, in bovine coronary endothelial cells, and arginase I is increased in the aorta of streptozotocin diabetic rats (Romero et al., 2008), causing endothelial dysfunction (Ishizaka et al., 2007; Romero et al., 2008).
Methylglyoxal (MG) is produced during glucose, fatty acid and amino acid metabolism to varying degrees (Thornalley, 1996). MG is a reactive dicarbonyl molecule which can react with arginine (Shipanova et al., 1997; Takahashi, 1977), lysine and cysteine residues (Ahmed et al., 1997) of exposed functional groups of proteins and enzymes and cause their structural and functional disruption (Dhar et al., 2010b; Jia et al., 2006). MG is a major precursor for the formation of advanced glycation end products (AGEs) and is clearly of great pathological significance (Kilhovd et al., 2003). Under physiological conditions the MG produced in the body is efficiently degraded by the glyoxalase enzymes and reduced glutathione (GSH) into D-lactate (Thornalley, 1993; Vander Jagt et al., 2003) to maintain plasma MG levels at around 1 μM or less. MG formation increases in diabetes (Thornalley, 1988) and diabetic patients have 3-4 fold elevated plasma MG levels (McLellan et al., 1994; Wang et al., 2007).

Incubation of vascular smooth muscle cells with 25 mM glucose or fructose for 3 h increases MG production 3.5 or 3.9 fold, respectively, and increases oxidative stress (Dhar et al., 2008). We have recently shown that in cultured rat aortic and human umbilical vein endothelial cells MG and high glucose reduced basal and bradykinin-stimulated nitric oxide (NO) production, cyclic guanosine monophosphate levels, and serine-1177 phosphorylation and activity of endothelial nitric oxide synthase (eNOS) without affecting threonine-495 and Akt phosphorylation, and total eNOS protein (Dhar et al., 2010b). Chronic treatment of Sprague-Dawley rats with MG for 4 weeks induces features characteristic of type 2 diabetes mellitus.

Evidently, safe and specific MG scavengers have the potential to prevent several different pathological conditions such as endothelial dysfunction, type 2 diabetes and AGEs formation. Currently, there is a lack of safe and specific MG scavengers. Several investigators have used
different compounds as MG scavengers, which have other actions and thus are non-specific and can even produce toxicity. These compounds include aminoguanidine (Brownlee et al., 1986; Edelstein et al., 1992), alagebrium (Dhar et al., 2010a; Little et al., 2005; Wolffenbuttel et al., 1998), N-acetyl cysteine (Jia et al., 2007; Vasdev et al., 1998) and metformin (Beisswenger et al., 2003; Ruggiero-Lopez et al., 1999; Wang et al., 2008). Since MG has been reported to have high affinity for arginine (Takahashi, 1977), our aim was to investigate and compare the effects of L-Arg and D-Arg on MG and high glucose-induced endothelial dysfunction and oxidative stress. We also examined the effects of MG on arginase expression and activity, which has not been reported previously.

6.3 Methods and materials

Animals

Male 11-week old Sprague-Dawley rats from Charles River Laboratories (Quebec, Canada) were used according to a protocol approved by the Animal Care Committee at The University of Saskatchewan, following guidelines of the Canadian Council on Animal Care. The investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). After one week of acclimatization, the rats were anesthetized with an inhalation of isoflurane (Forane, 4% in oxygen), delivered through a precision vaporizer and circle absorption breathing system (Ohio, 30/70 Proportioner Anesthesia Machine, Madison, Wisconsin). When anesthesia reached sufficient depth as determined by the absence of the leg flexor response and the eyelid reflex, the thorax was quickly opened by a midline incision and the rat was killed by cutting the heart open
and causing exsanguination. The aorta was quickly removed without damaging the endothelium and placed in a beaker filled with Kreb’s solution and bubbled with 95% O₂ + 5% CO₂.

**Isometric tension studies on aortic rings**

A group of 24 Sprague-Dawley rats was used. Isometric tension studies were carried out on rat aortic rings as described (Dhar et al., 2010b). Briefly, 3-4 mm thoracic aortic rings from Sprague-Dawley rat were mounted under a 2 g load in four separate 10 mL organ baths containing Krebs solution with 5 mM glucose and maintained at 37° C and bubbled with 95% O₂ + 5% CO₂. After a 90 min equilibration period the rings were pre-contracted with phenylephrine (1 µM) and cumulative concentration-dependent relaxation in response to acetylcholine (ACh) was obtained before (Control) and 2 h after incubation with either glucose (25 mM) or MG (100 µM) (Dhar et al., 2010b), or the nitric oxide synthase inhibitor, Nω-nitro-L-arginine methyl ester (L-NAME, 10 µM). In initial experiments the responses to ACh were repeated before and 2 h after incubation with normal Krebs solution to confirm reproducibility of responses to ACh. Some sets of rings were co-incubated with either L-Arg (300 µM) or D-Arg (300 µM) for 2 h. Treatment with each compound was tested in rings from at least 5 different rats. Isometric tension was measured with isometric force transducers with the ‘Chart’ software and Powerlab equipment (AD Instruments Inc., Colorado Springs, CO, USA).

**Methlyglyoxal assay**

MG was measured by a specific and sensitive HPLC method as described previously (Dhar et al., 2009). MG was derivatized with o-phenylenediamine (o-PD) to specifically form 2-
methylquinoxaline. The samples were incubated in the dark for 24 h with 0.45 N perchloric acid (PCA) and 10 mM o-PD at room temperature. Samples were centrifuged at 12000 rpm for 10 min. 2-methylquinoxaline and quinoxaline internal standard (5-methylquinoxaline) were quantified on a Hitachi D-7000 HPLC system (Hitachi, Ltd., Mississauga, ON, Canada) via Nova-Pak® C18 column (3.9×150 mm, and 4 μm particle diameter, Waters Corporation, Milford, MA, USA).

**Cell culture**

Rat thoracic aortic smooth muscle cell line (A-10 cells) was obtained from American Type Culture Collection and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal bovine serum (FBS) at 37°C in a humidified atmosphere of 95% air and 5% CO₂, as described in our previous studies (Dhar et al., 2008). A-10 cells were seeded either in 100 mm dishes for MG measurement or in 96-well plates for other assays, with an equal amount of cells (10⁶/mL) in each well, and cultured to confluence. For immunocytochemistry staining, cells were seeded on cover glass slides (2×10⁶/mL). Cells were starved in FBS-free DMEM for 24 h before exposure to different metabolic precursors.

Human umbilical vein endothelial cells (HUVECs) from American Type Culture Collection were cultured in Kaighn’s F12K medium containing 10% fetal bovine serum (FBS), 0.1 mg/mL heparin and 0.03-0.05 mg/mL endothelial cell growth supplement (Dhar et al., 2010b).
Western blotting

Cell lysates were prepared as described earlier (Dhar et al., 2010b; Dhar et al., 2011) and the protein concentration in the supernatant was determined by the BCA Protein assay (Bio-Rad, Hercules, CA, USA). Aliquots of cell lysates (50 μg of protein each) were separated on 7.5-10% SDS-PAGE, electrotransferred to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad), blocked with 5% nonfat milk in TBS-Tween buffer for 2 h at room temperature, and incubated overnight at 4° C with the primary antibodies to arginase I, arginase II, nuclear factor kappa B (NF-κB) or NADPH oxidase 4 (NOX4) (Santa Cruz, CA, USA), and then with horseradish peroxidase conjugated secondary antibody (Santa Cruz, CA, USA) for 1 h at room temperature. After extensive washing, the immunoreactive proteins were detected with an Enhanced Chemiluminescence Detection System (ECL; Amersham Biosciences Corp., Piscataway, NJ, USA) (Dhar et al., 2010b; Dhar et al., 2011).

Arginase activity assay

Arginase activity was measured using an arginase assay kit (BioAssays Systems, CA, USA). Arginase catalyses the conversion of arginine to ornithine and urea. Briefly, cell lysates were mixed with substrate arginine buffer and incubated for 2 h. Urea reagent was added to stop the reaction and the optical density measured at 430 nm.

Measurement of reactive oxygen species

Confluent cells were loaded with a membrane-permeable, nonfluorescent probe 2’,7’-dichlorofluorescin diacetate (CM-H2DCFDA, 5 μM) for 2 h at 37° C in FBS-free medium in the
dark. The cells treated with MG (30 μM) or glucose (25 mM) for 24 h were assayed for fluorescent oxidized dichlorofluoroscein (DCF) as an indicator of production of reactive oxygen species (ROS) as described earlier (Dhar et al., 2008; Dhar et al., 2010b). The protein content of the homogenate was measured by BCA Protein assay (Bio-Rad, Hercules, CA, USA).

**Immunocytochemistry**

A-10 cells were seeded on glass cover slips followed by incubation with different test compounds for 24 h, and subjected to staining for the MG-induced AGE, Nε-carboxyethyl lysine (CEL). As described previously (Dhar et al., 2008; Dhar et al., 2011), the treated cells were fixed in 4% paraformaldehyde for 30 min at room temperature and washed twice with 0.01 N phosphate buffered saline (PBS). After permeation with 0.1% Triton X-100 for 5 min and two washes with PBS, the cells were incubated with normal goat serum (diluted 1:30 in 0.1 N PBS) for 1 h to block non-specific binding sites. After shaking off the goat serum the slides were incubated with the CEL antibody (1:100; a generous gift from Novo Nordisk, A/S, Denmark) overnight at room temperature. Cells were washed twice in PBS (0.01 N) for 5 min and incubated with secondary fluorescein isothiocynate (FITC) conjugated anti-CEL antibody (Molecular Probes) for 2 h. After washing thrice with PBS the slides were mounted in glycerol:PBS (3:7), coverslipped and observed under a fluorescence microscope. Staining intensity was quantified using the Metamorph image analysis software (v. 7, Molecular Devices). Slides from four different experiments were analyzed with 5 fields per slide observed and averaged.
Chemicals and statistical analysis

All chemicals were of analytical grade. Methylglyoxal, D-glucose, L-arginine and D-arginine were purchased from Sigma Aldrich, Oakville, ON, Canada. Cell culture media and reagents were purchased from Invitrogen Canada Inc., Burlington, ON, Canada. Data are expressed as mean ± SEM and analyzed using one way ANOVA and post hoc Bonferroni’s test. The P value was considered significant when it was less than 0.05.

6.4 Results

L-arginine and D-arginine prevent methylglyoxal and high glucose induced reduction of acetylcholine-induced relaxation of aortic rings

In rat aortic rings precontracted with phenylephrine (1 µM), MG (100 µM, Fig. 6-1A, B) as well as high glucose (25 mM, Fig. 6-1C, D) incubated for 2 h in the bath caused significant inhibition of ACh-induced endothelium-dependent relaxation, which was prevented by coincubation of L-Arg (300 µM, Fig. 6-1A, C) or D-Arg (300 µM, Fig. 6-1B, D) with MG (Fig. 6-1A, B) or high glucose (Fig. 6-1C, D). Incubation of the eNOS inhibitor, Nω-nitro-L-arginine methyl ester (L-NAME 10 µM, Fig. 6-1E, F) prevented ACh-induced relaxation, which was restored by co-incubation of L-Arg (300 µM, Fig. 6-1E), but not D-Arg (300 µM, Fig. 6-1F), with L-NAME.

L-Arg and D-Arg (300 µM) did not affect ACh-induced relaxation of the rings (data not shown). MG and glucose did not affect endothelium-independent relaxation of aortic rings induced by sodium nitroprusside (data not shown).
L-arginine and D-arginine prevent high glucose-induced elevation of methylglyoxal levels in vascular smooth muscle cells

Incubation of VSMCs with MG (30 µM) (Fig. 6-2A) or high glucose (25 mM) (Fig. 6-2B) for 24 h significantly increased the level of cellular MG to a similar extent, which was prevented by coincubation with L-Arg or D-Arg (300 µM) (Fig. 6-2). L-Arg or D-Arg alone did not affect basal MG levels in VSMCs (Fig. 6-2).

Methylglyoxal and high glucose increase arginase I and II expression and activity

Incubation of HUVECs (Fig. 6-3A, C) or VSMCs (Fig. 6-3B, D) with MG (30 µM) (Fig. 6-3A, B) or high glucose (25 mM) (Fig. 6-3C, D) for 24 h significantly increased arginase I and II protein expression in both cell types, which was attenuated by co-incubation with L-Arg (300 µM) or D-Arg (300 µM).

Incubation of VSMCs with MG (30 µM) or high glucose (25 mM) for 24 h significantly increased total arginase activity (Fig. 6-3E). L-Arg (300 µM) or D-Arg (300 µM) co-incubated with MG or high glucose further increased arginase activity (Fig. 6-3E). However, L-Arg (300 µM) or D-Arg (300 µM) alone did not increase arginase activity (Fig. 6-3E).

L-arginine and D-arginine prevent methylglyoxal and high glucose-induced increased expression of nuclear factor κB and NADPH oxidase 4

Incubation of cultured HUVECs (Fig. 6-4A, C) or VSMCs (Fig. 6-4B, D) with MG (30 µM) (Fig. 6-4A, B) or with high glucose (25 mM) (Fig. 6-4C, D) for 24 h significantly increased
the protein expression of NF-κB and NOX4 in both cell types, which was attenuated by co-incubation with L-Arg (300 µM) or D-Arg (300 µM) (Fig. 6-4).

**L-arginine and D-arginine prevent methylglyoxal and high glucose-induced oxidative stress**

Incubation of cultured HUVECs (Fig. 6-5) or VSMCs (Fig. 6-6) with MG (30 µM or 100 µM) (Figs. 6-5A, B and 6-6A, B), or with high glucose (25 mM) (Figs. 6-5C and 6-6C) for 3 h or 24 h significantly increased oxidative stress as measured by oxidized dichlorofluorescein. Both L-Arg (300 µM) and D-Arg (300 µM) co-incubated with MG or glucose attenuated the increase in oxidative stress (Figs. 6-5 and 6-6). L-Arg and D-Arg alone did not affect basal DCF levels (data not shown).

**L-arginine and D-arginine prevent methylglyoxal and high glucose-induced increased formation of Nε-carboxyethyl lysine (CEL)**

Incubation of cultured VSMCs with MG (30 µM) or with high glucose (25 mM) (Figs. 6-5C and 6-6C) for 24 h significantly increased the formation of the MG-specific AGE, CEL (bright green stain) (Fig. 6-7). Co-incubation with L-Arg (300 µM) or D-Arg (300 µM) attenuated the formation of CEL (Fig 6-7).

**6.5 Discussion**

We aimed to investigate the potential of arginine as a MG scavenger by focusing on endothelial dysfunction induced by MG and high glucose. We have reported the molecular
mechanisms of eNOS dysfunction caused by MG and high glucose in a recent paper (Dhar et al., 2010b), so we investigated whether L-Arg and D-Arg can attenuate MG and high glucose-induced reduced ACh-induced relaxation in aortic rings. Additionally and importantly, we also considered effects on arginase since it has been recognized as a contributor to endothelial dysfunction (Berkowitz et al., 2003; Ishizaka et al., 2007) and also uses L-Arg as a substrate (Morris, 2009). We report the following novel findings: 1. MG up regulates arginase I and arginase II protein expression in cultured HUVECs and VSMCs, 2. MG increases arginase activity in VSMCs, 3. high glucose up regulates arginase I and II protein expression and activity in VSMCs, 4. L-Arg and D-Arg attenuate the effects of MG and high glucose in rat isolated aortic rings and cultured HUVECs and VSMCs for the parameters tested except for increased arginase activity, and the effect of L-Arg and D-Arg against MG and high glucose is most likely independent of eNOS.

We examined endothelial dysfunction, which is a hallmark of prediabetes (Su et al., 2008), type 1 and type 2 diabetes (De Vriese et al., 2000; Potenza et al., 2009) and precedes the development of cardiovascular complications of diabetes (De Vriese et al., 2000; Potenza et al., 2009; Su et al., 2008). It has been widely ascribed to reduced NO availability (De Vriese et al., 2000; Dhar et al., 2010b; Potenza et al., 2009). We have recently shown that MG and high glucose cause reduced serine 1177 phosphorylation and activity of eNOS, NO production and ACh-induced endothelium-dependent relaxation, which was prevented by the MG scavenger aminoguanidine (Dhar et al., 2010b).

L-Arg as well as D-Arg attenuated the reduced ACh-induced endothelium dependent relaxation of the aortic rings, but only L-Arg prevented the inhibition of ACh-induced relaxation
by the NOS inhibitor, L-NAME (Fig. 6-1). L-Arg, but not D-Arg, is a substrate of NOS (Palmer et al., 1988) and since D-Arg also prevented MG and high glucose-induced reduced relaxation but not that caused by L-NAME, it strongly suggests that arginine prevents MG and high glucose-induced reduced relaxation by an eNOS independent mechanism.

One of the deleterious effects of MG and high glucose is an increase in oxidative stress (Dhar et al., 2008; Dhar et al., 2010b; Wu et al., 2002), which can be attributed to increased activity of NADPH oxidase (Dhar et al., 2010b) and NF-κB (Wu et al., 2002). We have recently shown that MG and high glucose cause reduced ACh-induced relaxation of aortic rings partly by increasing NADPH oxidase activity and oxidative stress (Dhar et al., 2010b). In this study L-Arg and D-Arg attenuated the increased expression of NOX4 and NF-κB (Fig.6-4) and increased production of free radicals caused by MG and high glucose (Figs. 6-5, 6-6). Oxidative stress can be increased by multiple mechanisms. MG is a key inducer of oxidative stress (Desai et al., 2008) and scavenging MG would prevent activation of multiple pathways of increased free radical generation.

Arginase has also been implicated in causing endothelial dysfunction, mainly by competing with eNOS for the common substrate, L-Arg (Berkowitz et al., 2003; Romero et al., 2008). If L-Arg and D-Arg are to be used to attenuate the effects of MG or high glucose, then their effects on arginase activity have to be considered. High glucose has been reported to cause increased expression of arginase in endothelial cells (Romero et al., 2008). The effect of MG on arginase has not been studied. We report for the first time that MG increases arginase I and II expression in endothelial cells and VSMCs. We also found that high glucose also increases arginase I and II expression in VSMCs (Fig. 6-3) besides endothelial cells. L-Arg and D-Arg
attenuated the increased arginase expression caused by MG and high glucose in both cell types (Fig. 6-3), possibly by scavenging MG. MG and high glucose also increased the activity of arginase, which seems to be independent of increased protein expression because, even when the protein expression of arginase was normalized by co-treatment with MG or high glucose and L-Arg or D-Arg, we still observed increased arginase activity (Fig. 6-3). Moreover, L-Arg and D-Arg alone did not increase arginase activity. While, the increased arginase activity seen with MG or high glucose plus L-Arg can be explained by increased substrate availability, the increased arginase activity seen with MG or high glucose plus D-Arg is surprising and needs further evaluation. One very assuring finding is that the use of L-Arg or D-Arg to prevent the deleterious effects of MG and high glucose on endothelial function or possibly on other biological functions, will not be compromised by their effects on arginase or eNOS.

A major deleterious effect of high glucose and reactive dicarbonyl metabolic intermediates, such as MG, glyoxal and 3-deoxyglucosone, is the formation of AGEs (Ahmed et al., 1997; Glomb et al., 2001; Kilhovd et al., 2003; Shipanova et al., 1997), which are strongly implicated in the pathogenesis of several conditions such as vascular complications of diabetes, neurodegenerative diseases, atherosclerosis and aging (Vlassara et al., 1994). The attenuation of the formation of the MG-specific AGE, CEL, in VSMCs (Fig. 6-7) is very promising in this regard. Prevention of dicarbonyls-induced AGEs, which is a major source of AGEs formation (Kilhovd et al., 2003; Mostafa et al., 2007; Vlassara et al., 1994), by safer and specific scavengers of reactive dicarbonyls is an attractive therapeutic option. The potential of L-Arg and D-Arg in this regard is discussed below.
Besides its effects on endothelial function, MG has other effects. Thus, acute and chronic MG cause pancreatic β cell dysfunction, reduced adipose tissue glucose uptake, reduced insulin secretion and type 2 diabetes in Sprague-Dawley rats (Dhar et al., 2010a; Dhar et al., 2011). MG has been shown to modify insulin making it dysfunctional (Jia et al., 2006), and LDL making it more atherogenic (Rabbani et al., 2011). Scavengers of MG can be very effective in preventive strategies against the deleterious effects of hyperglycemia, hyperfructosemia (another source of MG) (Dhar et al., 2008) and elevated MG levels.

Unfortunately, specific and safe MG scavengers are not available. The compounds currently used for their MG scavenging ability are non-specific and have other effects, which can even be toxic. Aminoguanidine is the most widely used MG scavenger and AGEs inhibitor (Brownlee et al., 1986; Edelstein et al., 1992), which unfortunately proved toxic in clinical trials (Bolton et al., 2004; Freedman et al., 1999). Metformin, an orally used drug to reduce hyperglycemia in type 2 diabetes, and N-acetyl cysteine also have MG scavenging ability but have other effects (Beisswenger et al., 2003; Jia et al., 2007; Millea, 2009; Ruggiero-Lopez et al., 1999; Vasdev et al., 1998). MG has great affinity for L-Arg and is proposed to react rapidly with the guanidino group of L-Arg (Takahashi, 1977). Since arginine has strong affinity for MG, it is highly likely that arginine binds MG, administered from outside and produced from glucose and other sources in the body, and thus, attenuates the deleterious effects of MG and high glucose on endothelial function. While L-arginine is used as a nutritional supplement, it is a substrate for five different enzymes including eNOS and arginase (Morris, 2009). The metabolic consequences of orally administered L-Arg, which is known to enter multiple metabolic processes in the liver and the body, are difficult to predict. D-Arg, the inactive isomer of L-Arg,
may prove to have more attractive pharmacokinetic and pharmacodynamic properties, and therapeutic potential than L-Arg, if its MG scavenging ability can be demonstrated to be specific at multiple functional and biochemical levels. Thus, D-Arg needs to be evaluated more rigorously for its pharmacokinetic properties and metabolic fate.

In conclusion, L-Arg and D-Arg attenuate MG and high glucose induced endothelial dysfunction, by an eNOS independent mechanism, most probably by binding and inactivating MG, given from outside or produced from high glucose. MG increases arginase I and II expression and activity. L-Arg and D-Arg attenuate the increased protein expression but not the increased activity of arginase induced by MG and high glucose, which did not restrict the attenuation of endothelial dysfunction. The effects of L-Arg and D-Arg on the other deleterious effects of MG and high glucose, need to be evaluated by many more separate studies, for example on MG-induced pancreatic islet dysfunction and insulin resistance, before definitive statements on their therapeutic potential can be made.

Acknowledgements

This work was supported by a grant-in-aid from the Heart and Stroke Foundation of Saskatchewan to KD and LW, and by a New Investigator grant from the Saskatchewan Health Research Foundation to KD.
Figure 6-1. L-arginine and D-arginine attenuate MG and high glucose induced, but not inhibition of eNOS-induced, reduced endothelium-dependent relaxation in isolated aortic rings from Sprague-Dawley rats.
Concentration-related responses were obtained to ACh in phenylephrine (PE, 1 μM) precontracted rings before (control) and 2 h after incubation with MG (100 μM) (A and B), or glucose (Glu, 25 mM) (C and D) or 15 min after incubation with the eNOS inhibitor L-NAME (10 μM) (E and F). In some sets of rings L-arginine (L-Arg, 300 μM) or D-arginine (D-Arg, 300 μM) was preincubated for 15 min followed by co-incubation for 2 h with MG (100 μM) (A and B), or Glu (25 mM) (C and D) or for 15 min with L-NAME (10 μM) (E and F). (n = 6 rings from different rats for each treatment group). *P<0.05, **P<0.01, ***P<0.01 vs. corresponding control values. †P<0.05, ††P<0.01, †††P<0.001 vs. corresponding L-Arg or D-Arg co-treated values. ‡‡P<0.01, ‡‡‡P<0.001 vs. corresponding control values.
Figure 6-2. Exogenous methylglyoxal (MG) and high glucose and increase cellular MG levels in cultured vascular smooth muscle cells: attenuation by L-arginine and D-arginine.

Confluent rat aortic vascular smooth muscle cells were incubated with normal culture medium (Control, Con) or medium containing MG (30 μM) (A), or glucose (25 mM) (B), for 24 h. L-arginine (L-Arg, 300 μM) or D-arginine (D-Arg, 300 μM) was incubated alone or with MG (30 μM) (A) or glucose (25 mM) (B) for 24 h. Cellular MG was measured by HPLC. n = 6 for each treatment. ***P<0.001 vs. corresponding control value, †††P<0.001 vs. corresponding MG (30 μM) (A), or glucose (25 mM) value (B).
Figure 6-3. Attenuation by L-arginine and D-arginine of methylglyoxal (MG) and high glucose-induced increased protein expression, but not activity of arginase (Agn) I and II in
cultured human umbilical vein endothelial cells (HUVECs) and vascular smooth muscle cells (VSMCs).

Cultured confluent HUVECs (A, C) or VSMCs (A-10 cell line) (B, D, E) were incubated with MG (30 µM) or glucose (Glu, 25 mM) for 24 h. In separate dishes L-arginine (L-Arg, 300 µM) or D-arginine (D-Arg, 300 µM) was incubated alone (E) or coincubated with MG (30 µM) or glucose (25 mM) for 24 h following which the arginase I and arginase II proteins were determined by western blotting (A-D). In (E) an arginase activity assay was performed 24 h after the treatments, based on conversion of arginine to ornithine and urea, using an activity assay kit. 

\( n = 6 \) for each group. **P<0.001 vs. control, ††P<0.01, †††P<0.001 vs. corresponding MG 30 µM or glucose 25 mM value.
Figure 6-4. Attenuation by L-arginine and D-arginine of methylglyoxal (MG) and high glucose-induced increased protein expression of nuclear factor kappa B (NF-κB) and NADPH oxidase 4 (NOX-4) in cultured human umbilical vein endothelial cells (HUVECs) and vascular smooth muscle cells (VSMCs).

Cultured confluent HUVECs (A, C) or VSMCs (A-10 cell line) (B, D) were incubated with MG (30 µM) or glucose (Glu, 25 mM) for 24 h. In separate dishes L-arginine (L-Arg, 300 µM) or D-arginine (D-Arg, 300 µM) was coincubated with MG (30 µM) or glucose (25 mM) for 24 h following which the NF-κB and NOX-4 proteins were determined by western blotting.
Figure 6-5. Attenuation by L-arginine and D-arginine of methylglyoxal (MG) and high glucose-induced increased reactive oxygen species production in cultured human umbilical vein endothelial cells (HUVECs).
Incubation of cultured HUVEC with MG (30 µM) (A), or MG (100 µM) (B) or glucose (25 mM) (C) for 3 h or 24 h increased reactive oxygen species (ROS) production, measured as oxidized dichlorofluorescein (DCF), which was attenuated by co-incubation with either L-arginine (L-Arg, 300 µM) or D-arginine (D-Arg, 300 µM). \( n = 8 \) for each group. **\( P<0.01 \), ***\( P<0.001 \) vs. corresponding control, \( \dagger\dagger\dagger P<0.001 \) vs. corresponding MG (30 µM), or MG (100 µM), or glucose (25 mM) value.
Figure 6-6. Attenuation by L-arginine and D-arginine of methylglyoxal (MG) and high glucose-induced increased reactive oxygen species production in cultured rat aortic VSMCs.
vascular smooth muscle cells (VSMCs).

Incubation of cultured VSMCs (A-10 cell line) with MG (30 μM) (A), or MG (100 μM) (B) or glucose (25 mM) (C) for 3 h or 24 h increased reactive oxygen species (ROS) production, measured as oxidized dichlorofluorescein (DCF), which was attenuated by co-incubation with either L-arginine (L-Arg, 300 μM) or D-arginine (D-Arg, 300 μM). $n = 8$ for each group. $***P<0.001$ vs. corresponding control, $†††P<0.001$ vs. corresponding MG (30 μM), or MG (100 μM), or glucose (25 mM) value.
Figure 6-7. Detection of methylglyoxal-induced advanced glycation endproduct (AGESs). N\textsuperscript{ε}-carboxyethyl-lysine (CEL).

AGEs in cultured rat aortic vascular smooth muscle cells (A-10 cells) were detected after incubation with MG (30 µM) or glucose (25 mM) alone, or coincubated with either L-arginine (L-Arg, 300 µM) or D-arginine (D-Arg, 300 µM) for 24 h. Immunocytochemistry was performed on fixed cells with specific CEL antibody and fluorescein isothiocyanate (FITC) conjugated secondary antibody. Scale bar 10 µm.
### Table 6-1. Methylglyoxal incubation assay

Methylglyoxal (MG) was incubated with L-arginine (L-Arg), D-arginine (D-Arg) or N-acetyl cysteine (NAC) in PBS at 37°C for different times. The solution was analyzed for free MG by HPLC after the given incubation period. The values are expressed as mean ± SEM (n = 6 each). *** $P < 0.001$ vs. MG alone.
CHAPTER 7

DISCUSSION AND CONCLUSIONS
7.1 GENERAL DISCUSSION

The association of diabetes and hypertension is well known. It adds to the treatment challenges of diabetes. The pathogenesis of hypertension in diabetics is unclear. For example, it is not clear if it is due to hyperglycemia *per se* or due to insulin resistance or some other cause. It may even be due to obesity (Go *et al.*, 2013; Landsberg *et al.*, 2013) which is the highest risk factor for type 2 diabetes. Up regulation of the RAAS has been reported in diabetes (Hsueh and Wyne, 2011; Goossens, 2012). Our lab has reported an elevated level of plasma and tissue MG in SHR and fructose fed SD rats, an animal model of insulin resistance that also develops hypertension (Wang *et al.*, 2005; Wang *et al.*, 2008). High fructose-diet in SD rats (Wang *et al.*, 2008) had increased plasma and aortic MG levels, and significantly increased BP. However, the molecular mechanisms were not examined and it was not clear whether the elevated MG levels were the cause or effect of hypertension. For example, one popular theory proposes that metabolism of fructose by fructokinase, mainly in the liver, consumes ATP and raises tissue and plasma levels of uric acid (Johnson *et al.*, 2007; Stirpe *et al.*, 1970). Elevated uric acid reduces NO production in endothelial cells and the kidney, and causes endothelial dysfunction and increased renin secretion (Mazzali *et al.*, 2001). Thus, in the high fructose-diet study (Wang *et al.*, 2008) it is possible that elevated BP may be caused by increased MG levels. Similarly, in the SHR (Wang *et al.*, 2004; Wang *et al.*, 2005), it was not clear whether the hypertension was caused by elevated MG in the plasma, the aorta and the kidney. The molecular mechanisms were not addressed in these studies. To evaluate whether MG is directly involved in the pathogenesis of hypertension, the logical step was to administer MG to normal animals, such as Sprague-
Dawley rats and to investigate whether it induces hypertension and if so what is/are the possible mechanism/s.

MG was administered to SD rats for some preliminary data. It is a known fact that MG is a potent inducer of oxidative stress, and oxidative stress has been implicated as one of the causative factors of hypertension. Also, up regulation of the RAAS has been reported in hyperglycemia. Increased oxidative stress and RAAS are known to feed each other (Hitomi et al., 2007). Since increased MG, oxidative stress, and RAAS have links it was hypothesized that MG up regulates RAAS, but this idea has not been tested before. Some common mediators of the RAAS are the AT₁ receptor for angiotensin, Ang II and adrenergic α₁ receptor. It was therefore decided to look at these parameters in cultured VSMCs treated with MG or high glucose. The initial experiments on VSMCs treated with MG were positive. Therefore, I made a protocol to treat SD rats with MG.

MG was administered to rats in drinking water in preliminary studies, and it did not significantly increase the plasma MG levels. One possible reason for this could be that MG being highly reactive is likely to react with proteins in the epithelial cells of the intestines, as reported in one study (Baskaran et al., 1990). This might hinder the absorption of MG. MG is most likely generated continuously within the body from the ongoing metabolic processes. To simulate this situation as best as possible, MG was administered by continuous infusion with a minipump. Our lab has had great success with this mode of administration in a previous study (Dhar et al., 2011) where the plasma concentration significantly increased to values reported in pathological conditions.
Treatment of SD rats with MG for 4 weeks resulted in a significant increase in the BP, and MG in the plasma, aorta and the kidney. The kidney plays a major role in BP regulation and RAAS activity, therefore, elevation of renal MG levels was of great interest. There was an elevation of plasma catecholamines, renin, angiotensin and aldosterone levels in MG treated rats, which was building up our evidence of up regulated RAAS. The effectors of RAAS were investigated and there was an increased expression of angiotensinogen, AT₁, α₁D, and renin in aorta and/or kidney of MG treated rats. One reason for choosing the aorta is that the expression of tissue RAAS has been well studied in the aorta (Campbell, 1987; Holycross et al., 1992; Naftilan et al., 1989). For example, the activity of VSMCs RAS is increased in conditions such as hypertension and atherosclerosis (Dzau, 1993). There were not enough of fat free mesenteric vessels to determine angiotensinogen, AT₁, α₁D in this tissue. To investigate the possible molecular mechanisms of how MG caused up regulation of the RAAS, cultured VSMCs were used, where interference from interacting factors found in vivo can be avoided. Normally, activation of a receptor by a ligand produces its effects through a simple or complicated signal transduction process. RAGE is a receptor for AGES. It has two main functions. The membrane bound RAGE is believed to increase oxidative stress in response to stimulation by AGES. However, MG has never been investigated as a ligand for RAGE. This idea was tested for the first time, and showed that silencing of RAGE prevented the increase in the expression of NF-κB, a key trigger of increased oxidative stress (Wu et al., 2002; Desai and Wu, 2008). So it established a likely initiating point for the signal transduction of MG that up regulates the RAAS and increases BP. Next I tried inhibiting NF-κB with CAY10512. Surely enough, inhibition of NF-κB prevented the increase in AT₁ and α₁D receptors in VSMCs. Ang II is known to up
regulate its own receptor and also NF-κB. To further establish the signal transduction I silenced angiotensionogen and was able to attenuate the increase in AT$_1$, α$_{1D}$, and also NF-κB, caused by MG. NF-κB can activate several oxidative stress pathways.

High dietary carbohydrates have been shown to increase BP in animal and human studies. High fructose levels in the diet in the form of sugar and high fructose corn syrup have created great controversy about their adverse health effects (Lustig et al., 2012; Lustig, 2010). The main dietary carbohydrate in our diet is sucrose, in the form of table sugar and high fructose corn syrup (HFCS). Sucrose in the form of table sugar is broken down into one molecule of fructose and glucose each in the body. On the other hand high fructose corn syrup is prepared by mixing free glucose and fructose in different proportions. The two most commonly used form of high fructose corn syrup are HFCS 55 (55% fructose and 42% glucose) and HFCS 42 (42% fructose and 53% glucose) (Fulgoni, 2008). Glucose and fructose are metabolized differently in the body (Bruckdorfer et al., 1973; Johnson et al., 2007; Johnson et al., 2009; Nakagawa et al., 2006; Wolfe et al., 1977), yet a high glucose, high fructose as well as a high sucrose diet have all been shown to increase BP in animal and human studies (Raben et al., 2002; Israel et al., 1983; Tom et al., 2011; Kaufman et al., 1991; Hwang et al., 1987; Jia & Wu, 2007). Male SD rats fed a high glucose diet developed a 7% increase in BP compared to rats fed a normal diet (Kaufman et al., 1991). SD rats fed with a diet containing 66% fructose as a percentage of total calories for approximately 2 weeks developed a significant increase in systolic BP from 124 ± 2 to 145 ± 2 (SEM) mmHg, whereas no change occurred in the control group (Hwang et al., 1987). Even lower doses of fructose (10% in drinking water) given to SD rats for 8 weeks induced a significant increase in systolic BP and microvascular changes in the kidney (Sanchez-Lozada et
In a study performed in Dr Wu’s lab, male SD rats fed a 60% fructose diet for 16 weeks showed an increase in the BP from about 110 mmHg to about 155 mmHg at the end of 16 weeks of treatment, along with an associated increase in serum MG levels from 2.48 ± 0.3 µmol/L in the control to 4.28 ± 0.5 µmol/L in the fructose treated rats (Wang et al., 2008). The increase in the BP in fructose treated rats was attenuated by co-treatment with metformin, a MG scavenger (Wang et al., 2008). Although MG was not established as a direct causative factor for the increased BP in the study by Wang et al (2008), the finding assumes great significance because fructose is a known precursor of MG (Dhar et al., 2008) and serum MG was significantly elevated in fructose treated rats (Wang et al., 2008). Fructose is equipotent to glucose in producing MG when metabolized (Dhar et al., 2008). In the present study, a high fructose-diet was fed to SD rats for 16 weeks, and it resulted in a significant increase in the BP, MG levels, angiotensin, AT1 receptor, α1D receptor protein and mRNA expression in the aorta and the kidney. There was also a significant increase in NF-κB and RAGE protein expression, and reduction in GSH levels in both the kidney and the aorta of fructose treated rats. Our results strongly support MG as a mediator of the effects of high fructose diet on the RAAS and the BP. In one of the ongoing studies in our lab, both high glucose (60% of total calories) and high fructose (60% of total calories) diets fed to 10 week old male SD rats for 12 weeks caused a similar significant increase in the BP. Thus, the BP in high glucose treated rats was 139 ± 3** mm Hg, and in high fructose treated rats it was 136 ± 3* mm Hg, compared to 102 ± 11 mm Hg in the control group (*P<0.5, **P<0.01 vs control group) (unpublished results). One limitation in comparing the effects of a high fructose diet versus exogenously administered MG on BP and other hypertension-associated parameters is that the amount of MG generated from fructose in
different organs and tissues can be expected to depend on the amount of fructose metabolized in a given organ/tissue. The amount of MG generated from fructose in a given organ/tissue can also be expected to be different or similar to exogenously administered MG depending on which organs/tissues receive the administered MG.

One major limitation in designing protocols for this project was the choice of a good MG scavenger. The commonly used MG scavengers include aminoguanidine, N-acetyl cysteine and metformin. N-acetyl cysteine has marked antioxidant effects which can complicate interpretation of results, especially since MG induces oxidative stress. Aminoguanidine is not suitable for \textit{in vivo} studies because of its other effects besides MG scavenging, such as inhibition of NOS and histaminase. Aminoguanidine may prove toxic over 16 weeks of administration. Metformin, a clinically used compound for type 2 diabetes, is a known MG scavenger and would not cause toxicity in a 16 week \textit{in vivo} study. However, the insulin sensitizing effect of metformin can make interpretation of results difficult. To overcome this dilemma to a certain extent, the MG scavenging effect of metformin was tested in cultured VSMCs where the \textit{in vivo} hepatic and other effects of metformin would not interfere with results, and the observed results can be attributed to metformin’s MG scavenging action. An \textit{in vitro} MG scavenging assay was also performed by incubating MG with metformin (Dhar \textit{et al.}, 2013). The results allowed to me conclude that MG is a likely mediator of the hypertensive effects of high fructose, through an up regulation of the RAAS.

Arginine seems to be an attractive potential MG scavenger because of several reasons. Arginine has been shown to have affinity for MG and other aldehydes. Arginine is an amino acid and supplements of L-Arg are used over the counter for several conditions. Its use in
hypertension is based on the assumption of increased availability of NO. If the MG scavenging potential can be realized in vivo then it can be an attractive supplement in diabetes. It can be argued that besides NOS, L-Arg is a substrate for several other enzymes, such as arginase. This can lead to unexpected effects when L-Arg is taken as a supplement. This fact is acknowledged and for this reason D-Arg was compared with L-Arg for its MG scavenging action. D-Arg is equally effective as a MG scavenger. Important findings will likely emerge when both L-Arg and D-Arg are tested in in vivo models of diabetes. Much more remains to be done to establish arginine as a safe MG scavenger.

It is difficult to gauge the relative MG scavenging ability of different MG scavengers because of their multiple direct and indirect effects. For example, NAC can scavenge MG and it is also an antioxidant and it can also increase GSH levels in the body (Jia et al., 2006; Millea, 2009; Lauterberg et al., 1983; Vasdev et al., 1998). Thus, NAC can decrease MG levels directly by scavenging it, and also indirectly by increasing GSH which will increase degradation of MG by the glyoxalsae enzymes. An in vitro incubation assay can be performed using different MG scavengers incubated separately with MG for different time periods and measuring free MG at timed intervals.

7.2 CONCLUSIONS

The present study strongly indicates MG as one of the causative factor in the pathogenesis of hypertension, especially in high carbohydrate- and diabetes-induced hypertension. Although several studies have reported elevated MG levels in hypertensive and diabetic conditions, it is not clear whether MG is the cause or effect of these pathological
conditions. Chronic MG administration by mini pump for 28 days up regulates components of the RAAS in the plasma, kidney and the aorta, and significantly increases BP, which was attenuated by a MG scavenger. Activation of RAGE and NF-κB likely mediates the signal transduction triggered by MG. High fructose diet treated Sprague-Dawley rats show findings similar to MG treated rats and suggest a strong possibility of MG as the mediator of the deleterious effects of high fructose on the RAAS and BP.

The study has shown efficacy of arginine as a MG scavenger in vitro. Incubation of VSMCs and HUVECs with glucose and MG increases MG formation, oxidative stress and arginase I and II expression and activity, the latter being a novel finding. These effects were attenuated by amino acid L- and D-arginine.

The present study indicates that a high carbohydrate diet may cause daily abnormal elevations of MG levels in the plasma and tissues, which could result in vascular pathology. The severity and progression of these changes leading to hypertension depends on the health of the individual, any underlying oxidative stress, GSH levels and antioxidant defenses.

In conclusion, MG is one of the causative factors in the pathogenesis of hypertension and endothelial dysfunction. Development of specific MG scavengers like arginine will help prevent the progression of high carbohydrate induced hypertension and endothelial dysfunction.

7.3 LIMITATIONS OF THE STUDY

Peripheral resistance influences the BP. The resistance in small vessels such as the second and third order branches of the mesenteric artery contributes to BP regulation. Determination of vascular contractility and endothelium-dependent relaxation of small peripheral
resistance vessels is a useful parameter to study in hypertension related studies. I studied vascular contractility in aortic rings. The results showed a marginal increase in contractility to the $\alpha_1$ selective agonist phenylephrine. I attempted to study contractility with the angiotensin AT$_1$ receptor agonist Ang II, but the vessel became desensitized to Ang II after the first dose and I was unable to obtain a dose-response curve to Ang II. Vascular smooth muscle contractility studies in small resistance vessels using a myograph would have been a useful addition to the results and will be a priority consideration in future studies.

There is a lack of availability of specific and safe MG scavengers. This has been discussed in the introduction. Aminoguanidine has other effects besides its MG scavenging action and is not an ideal MG scavenger for in vivo experiments. I used alagebrium, which was kindly provided by Alteon Inc., USA, in initial experiments. Alagebrium was developed as an AGEs breaker but we have shown its MG scavenging action (Dhar et al., 2010a). It is not toxic in vivo. However, the company ceased operations and we were not able to replenish our supply and had to use aminoguanidine in later studies. Aminoguanidine being toxic in vivo we used metformin in high fructose treated rats. Metformin is used clinically in type 2 diabetes but is not a specific MG scavenger. For this reason the conclusions have been moderated in studies with high fructose diet fed rats and metformin. Even though I was convinced that elevated MG generation following high fructose intake mediates increased expression of RAAS components, I concluded that “we report a strong association between elevated levels of methylglyoxal, RAGE, NF-κB, mediators of the renin angiotensin system and blood pressure in high fructose diet fed rats.”
Another argument can be made that increased BP caused by increased RAAS activity should be prevented by inhibitors of angiotensin converting enzyme such as ramipril and enalapril, or with angiotensin receptor blockers such as losartan. Therefore, a group treated with MG plus an ACE inhibitor or angiotensin receptor blocker should have been included. My explanation is that there are many factors, such as inflammation, hyperglycemia, and obesity, which can increase RAAS activity. Chronic inflammation itself can occur in many conditions. Therefore prevention of increased BP with ACE inhibitors or angiotensin receptor blockers does not provide conclusive evidence that a given factor, in this case MG, was responsible for increased RAAS expression and BP.

The BP was measured with a carotid artery catheter at the end of the treatment periods in 4 week MG treated and 16 week fructose treated rats. While it can be argued that anesthesia can affect the recorded BP, I believe that the factor of anesthesia would affect all groups equally, including the control group. Therefore, the results bear significance. I tried to measure the BP weekly during treatment with a tail cuff system (Harvard Apparatus Canada, Saint-Laurent, QC, Canada), but I got very variable results in all groups. The BP value was different in successive recordings from the same rat on the same day. I experienced that tail cuff BP recording is not a very reliable method. It can be argued that telemetry is a reliable method to measure the BP. Telemetry is a very invasive procedure with major drawbacks of expertise needed, the extra post-surgical recovery time, the increase in expense and the limitations of fewer implants available at any given time. It was decided to use the option of telemetry recording if the results were inconclusive with carotid artery recording, in a separate follow up project, which was not required.
It can be argued that 60% calories provided by fructose in the diet is higher than the 10-15% fructose seen in North American diets, but 60% is widely used in animal studies by researchers, and 60% is expected to produce results comparable to 10-15% diet in a shorter time.

7.4 SIGNIFICANCE OF THE STUDY

Hypertension is a major problem in Canada and the whole world. Adding to the burden is the recent alarming epidemic of obesity and type 2 diabetes, attributed in a large part to high dietary carbohydrates. The cases of diabetes associated hypertension are bound to increase. For practical reasons compounds targeting glucose or fructose molecule itself cannot be used. Establishing excessive reactive aldehydes produced from high carbohydrate diet metabolism in the pathogenesis of diabetes and hypertension will allow us to develop preventive strategies. Preventive strategies will play an important role because the dietary habits of billions of people worldwide are unlikely to change overnight or even over the next few years. The results with MG have given important clues for more work in high carbohydrate diet induced hypertension. Our lab will investigate the potential of arginine as a preventive supplement against MG-induced pathology.
REFERENCES


Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. *Proc Natl Acad Sci USA* 95: 1301-1306.


151
77. Fulgoni V. (2008). High-fructose corn syrup (HFCS): Everything you wanted to know, but were afraid to ask. *Am J Clin Nutr* 88(6): 1715S.


Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: 

J Pharmacol Exp Ther 298: 403–410.

(1991) Purification and characterization of particulate endothelium-derived relaxing factor 
synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci USA 
88: 10480-10484.

dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem 16: 94-
112.


system. CNS Spectr 6: 656-662.

Glycation of LDL by methylglyoxal increases arterial atherogenicity: a possible 


an endogenous ligand for the G protein-coupled receptor Mas. 


